Ortaokul-Lise; Özel İzmir Amerikan Lisesi
Üniversite; Dokuz Eylül Üniversitesi Tıp Fakültesi (2001)
Dokuz Eylül Üniversitesi Tıp Fakültesi Üniversitesi Tıp Fakültesi İç Hastalıkları ABD, İç Hastalıkları Uzmanlık Eğitimi (2002-2008)
Dokuz Eylül Üniversitesi Tıp Fakültesi İç Hastalıkları ABD, Tıbbi Onkoloji Uzmanlık Eğitimi (2009-2013)
The Cleveland Klinik Harry R. Horvitz Palyatif bakım Ünitesi Kanser Merkezi, Taussig Kanser Enstitüsü, Cleveland, Ohio, A.B.D (2012)
Dokuz Eylül Üniversitesi Tıp Fakültesi Sağlık Bilimleri Enstitüsü Temel Onkoloji Anabilim Dalı, Temel Onkoloji Doktora Programı (2012-2017)
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study
By
Olmez, OF (Olmez, Omer Fatih) [1] , [16] ; Bilici, A (Bilici, Ahmet) [1] ; Er, O (Er, Ozlem) [2] ; Bisgin, A (Bisgin, Atil) [3] , [4] ; Sevinc, A (Sevinc, Alper) [5] ; Akman, T (Akman, Tulay) [6] ; Uslu, R (Uslu, Ruchan) [6] ; Mandel, NM (Mandel, Nil Molinas) [7] ; Yalcin, S (Yalcin, Suayib) [8] ; Teomete, M (Teomete, Mehmet) [9] ;
Group Author
TUMPACT Study Grp (TUMPACT Study Grp)
(provided by Clarivate)
Source
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume
54
Issue
5
Page
562-568
DOI
10.1093/jjco/hyae002
Published
MAY 7 2024
Early Access
JAN 2024
Indexed
2024-02-02
Document Type
Article
Jump to
Abstract
Translate Objective The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes.Methods The study encompassed 234 adult patients (mean age: 52.7 +/- 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response.Results Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16).Conclusion Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.
Our real-world study reveals complex molecular profiling significantly impacts treatment decisions for advanced solid tumour patients, though without significant differences in treatment responses.
Keywords
Author Keywords
advanced solid tumours next-generation sequencing
Evaluation of sleep disorders in cancer patients based on Pittsburgh Sleep Quality Index
By
Akman, T (Akman, Tulay) [1] ; Yavuzsen, T (Yavuzsen, Tugba) [2] ; Sevgen, Z (Sevgen, Zeynep) [3] ; Ellidokuz, H (Ellidokuz, Hulya) [4] ; Yilmaz, AU (Yilmaz, Ahmet Ugur) [5]
(provided by Clarivate)
Source
EUROPEAN JOURNAL OF CANCER CARE
Volume
24
Issue
4
Page
553-559
DOI
10.1111/ecc.12296
Published
JUL 2015
Indexed
2015-07-01
Document Type
Article
Abstract
Translate Insomnia, poor sleep quality and short sleep durations are the most common problems seen in cancer patients. More studies are needed about sleep disorders in cancer patients. In our study, we aimed to investigate the prevalence of sleep disorders and the impact of these problems on the quality of life in cancer patients. Pittsburgh Sleep Quality Index (PSQI) was given to a total of 314 patients. The psychometric evaluation of the Turkish version of PSQI in cancer patients revealed that 127 (40.4%) patients had global PSQI scores >5, indicating poor sleep quality. There was no statistically significant relationship between PSQI scores and sexuality, marital status, cancer stage and chemotherapy type (P > 0.05); while the patients with bone and visceral metastasis had much lower PSQI scores (P = 0.006). Patients with Eastern Cooperative Oncology Group performance scores of 3 or more had also significantly lower PSQI scores (P = 0.02). In conclusion, PSQI questionnaire may be used to evaluate the sleep disorders in cancer patients. Consistent use of multi-item measures such as PSQI with established reliability and validity would improve our understanding of difficulties experienced by cancer patients with chronic insomnia.
Keywords
Author Keywords
sleep disorders cancer patient Pittsburg Sleep Quality Index
The Preventive Effect of Oxytocin to Cisplatin-Induced Neurotoxicity: An Experimental Rat Model
By
Akman, T (Akman, Tulay) [1] ; Akman, L (Akman, Levent) [2] ; Erbas, O (Erbas, Oytun) [3] ; Terek, MC (Terek, Mustafa Cosan) [2] ; Taskiran, D (Taskiran, Dilek) [3] ; Ozsaran, A (Ozsaran, Aydin) [2]
(provided by Clarivate)
Source
Volume
2015
DOI
10.1155/2015/167235
Article Number
167235
Published
2015
Indexed
2015-01-01
Document Type
Article
Abstract
Translate Peripheral neurotoxicity is a frequent dose-limiting side effect of the chemotherapeutic agent cisplatin. This study was conducted to investigate the preventive effect of oxytocin (OT) on cisplatin-induced neurotoxicity in rats. Forty-four adult female rats were included in the study. Thirty-six rats were administered intraperitoneally (i.p.) single dose cisplatin 10mg/kg and divided in to 3 groups. The first group (n = 12) received saline i.p whereas the second group (n = 12) and the third group (n = 12) were injected with 80 mu g/kg and 160 mu g/kg OT, respectively, for 10 days. The remaining 8 rats served as the control group. Electromyography (EMG) studies were recorded and blood samples were collected for the measurement of plasma lipid peroxidation (malondialdehyde; MDA), tumor necrosis factor (TNF)-alpha and glutathione (GSH) levels. EMG findings revealed that compound muscle action potential amplitude was significantly decreased and distal latency was prolonged in the nontreated cisplatin-injected rats compared with the control group (P < 0.005). Also, nontreated cisplatin-injected rats showed significantly higher TNF-alpha and MDA levels and lower GSH level than control group. The administration of OT significantly ameliorated the EMG alterations, suppressed oxidative stress and inflammatory parameters, and increased antioxidative capacity. We suggest that oxytocin may have beneficial effects against cisplatin-induced neurotoxicity.
Keywords
Keywords Plus
DNA-DAMAGE OXIDATIVE STRESS CYTOTOXICITY ACTIVATION
Can Inflammatory and Nutritional Serum Markers Predict Chemotherapy Outcomes and Survival in Advanced Stage Nonsmall Cell Lung Cancer Patients?
By
Cehreli, R (Cehreli, Ruksan) [1] ; Yavuzsen, T (Yavuzsen, Tugba) [2] ; Ates, H (Ates, Halil) [3] ; Akman, T (Akman, Tulay) [4] ; Ellidokuz, H (Ellidokuz, Hulya) [1] ; Oztop, I (Oztop, Ilhan) [2]
(provided by Clarivate)
Source
Volume
2019
DOI
10.1155/2019/1648072
Article Number
1648072
Published
2019
Indexed
2019-03-22
Document Type
Article
Abstract
Translate Purpose. To determine the values of prognostic nutritional and inflammatory markers in chemotherapy outcomes and survival in the patients with advanced nonsmall cell lung cancer (NSCLC) and also in the secondary malnutrition and cachexia. Methods. Twenty-five patients with diagnosis of aNSCLC were registered for the prospective study. Malnutrition was determined by the Subjective Global Assessment (SGA) and performance status by criteria of the Eastern Cooperative Oncology Group (ECOG). Before treatment, serum levels of albumin, prealbumin, vitamin D, zinc (Zn), C-reactive protein (CRP), IL-6, IL-1 , TNF-, lipoprotein lipase (LPL), and the Glasgow Prognostic Score (GPS) were recorded. Patients were followed prospectively for treatment outcomes and survival. Results. Due to the deaths of 18 patients during the 4-month follow-up period, no adequate measurements of inflammatory and nutritional markers could be performed. However, seven patients completed the treatment period and evaluations of these markers could be performed during the three periods. Eighty-four percent of patients were male with a mean age of 63.3 +/- 8.7 years. Evaluation of the malnutrition by SGA showed that 5 (20%) patients were well nourished (A), 12(48%) were moderately malnourished (B), and 8(32%) were severely malnourished (C). Low levels of serum albumin (<3.5g/dl), prealbumin (<20 mg/ml), 25-hydroxycholecalciferol (<30 ng/ml), and Zn (<70mg/ml) were detected in 15(60%), 17(68%), 24 (96%), and 22 (88%) patients, respectively. Elevated levels of CRP (10 mg/L), IL6 (18pg/ml), TNF- (24pg/ml), IL-1 (10pg/ml), and LPL (<12pg/ml) were found in 24 (96%), 11(44%), 9(36), 13(52%), and 11(44%) patients, respectively. Moderate and severe malnutrition, acute phase response, and reduced survival were determined in patients with NCSLC. In 7 patients that completed the treatment period, there was an association between elevated serum levels of IL-6, IL-1, TNF-, CRP, and LPL and also the reduced serum levels of albumin, prealbumin, Zn, vitamin D, and GPS, respectively. Similarly, Friedman analysis indicated that prealbumin significantly increased (p=0.007) in the follow-up period. But the serum levels of CRP (mean 37.3 +/- 22.3; Wilcoxon test P=0.368) in the seven patients were lower than those of the 18 patients that expired (mean 75.82 +/- 56.2). Conclusion. Malnutrition and cachexia negatively influence oncological outcomes in patients with NSCLC. These nutritional/inflammatory markers may be useful for selection of high risk and reduced survival in patients with aNSCLC undergoing adjuvant chemotherapy.
Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients
By
Durnali, A (Durnali, Ayse) [1] ; Alkis, N (Alkis, Necati) [1] ; Cangur, S (Cangur, Sengul) [2] ; Yukruk, FA (Yukruk, Fisun Ardic) [3] ; Inal, A (Inal, Ali) [4] ; Tokluoglu, S (Tokluoglu, Saadet) [5] ; Seker, MM (Seker, Mehmet Metin) [6] ; Bal, O (Bal, Oznur) [1] ; Akman, T (Akman, Tulay) [7] ; Inanc, M (Inanc, Mevlude) [8] ;
(provided by Clarivate)
Source
Volume
30
Issue
3
DOI
10.1007/s12032-013-0624-6
Article Number
624
Published
SEP 2013
Indexed
2013-09-01
Document Type
Article
Abstract
Translate The aim of this retrospective, multicenter study was to evaluate clinicopathological characteristics, prognostic factors and treatment outcomes of teenage and adult patients with high-grade osteosarcoma. A total of 240 osteosarcoma patients who were diagnosed and treated from March 1995 to September 2011 were analyzed. Median age was 20 years (range 13-74 years), and 153 patients (63.8 %) were male. Primary tumor localization was extremity in 204 patients (85.4 %), trunk in 21 patients (8.8 %) and head and neck region in 14 patients (5.9 %). According to American Joint Committee on Cancer staging system, 186 patients (77.5 %) were stage II, 3 (1.3 %) were stage III and 48 (20.0 %) were stage IV. Median overall survival (OS) was 55 months (95 % CI 36.8-73.1 months). OS after 2, 5 and 10 years were 67, 49 and 42 %, respectively. Univariable analysis for OS showed that male gender (p = 0.032), high baseline lactate dehydrogenase (LDH) level (p < 0.001), high baseline serum alkaline phosphatase level (p = 0.002), telangiectatic subtype (p = 0.023), presence of metastasis at diagnosis (p < 0.001), presence of tumor positive margins after primary surgery (p = 0.015), poor pathological response to preoperative chemotherapy (p = 0.006) and presence of recurrent disease during follow-up period (p < 0.001) were significantly associated with poor survival. Patientswho received postoperative methotrexate plus doxorubicin plus cisplatin (M + A + P) combination regimen (p = 0.019), underwent surgery for recurrent disease (p < 0.001) and received chemotherapy for recurrent disease (p < 0.001) had longer OS. Inmultivariable analysis for OS, only high LDH level (p = 0.002) and the presence of metastasis at diagnosis (p = 0.011) were associated with poor OS, whereas the patients who received chemotherapy for recurrent disease had a longer OS (p = 0.009).
Keywords
Author Keywords
Adult Teenage Osteosarcoma Prognostic factors
Predictors of functional capacity in colorectal cancer patients
By
Tomruk, M (Tomruk, Murat) [1] ; Karadibak, D (Karadibak, Didem) [1] ; Yavuzsen, T (Yavuzsen, Tugba) [2] , [3] ; Akman, T (Akman, Tulay) [4]
(provided by Clarivate)
Source
Volume
23
Issue
9
Page
2747-2754
DOI
10.1007/s00520-015-2639-3
Published
SEP 2015
Indexed
2015-08-17
Document Type
Article
Abstract
Translate The aim of this study is to determine the predictors of functional capacity and explore the relationship between functional capacity, performance status, fatigue, quality of life, anxiety, and depression in colorectal cancer (CRC) patients.
Forty-two patients diagnosed as stage II-III CRC according to tumor, node, metastasis (TNM) classification were included the study. Functional capacity, performance status, fatigue, quality of life, anxiety, and depression of CRC patients were assessed using six-minute walk distance (6MWD) in the six-minute walk test (6MWT), Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Colorectal (FACT-C), and Hospital Anxiety and Depression Scale (HADS), respectively. A multiple linear regression model was used to identify independent predictors of functional capacity.
The six-minute walk distance (6MWD) was intermediately and negatively correlated with ECOG-PS score (p = 0.001, r = -0.415), BFI-impact of fatigue on daily functioning score (p = 0.013, r = -0.379), and age (p = 0.040, r = -0.319). An intermediate and positive correlation was found between 6MWD and FACT-C score (p = 0.016, r = 0.369). The multiple regression analysis revealed that only ECOG-PS score was significant and independent predictor of the 6MWD, accounted for 34.8 % of the variance.
Performance status was found to be the only significant predictor of functional capacity in this study. Assessing performance status may have an essential role in order to predict functional capacity in CRC patients. Future studies that include a larger sample size would more clearly elucidate the predictors and relationships of functional capacity.
Keywords
Author Keywords
Colorectal cancer Functional capacity Performance status Quality of life
The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status
By
Akman, T (Akman, Tulay) [1] ; Oztop, I (Oztop, Ilhan) [2] ; Baskin, Y (Baskin, Yasemin) [3] ; Unek, IT (Unek, Ilkay Tugba) [2] ; Demir, N (Demir, Necla) [2] ; Ellidokuz, H (Ellidokuz, Hulya) [3] ; Yilmaz, AU (Yilmaz, Ahmet Ugur) [4]
(provided by Clarivate)
Source
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Volume
12
Issue
1
Page
96-102
DOI
10.4103/0973-1482.148684
Published
JAN-MAR 2016
Indexed
2016-07-13
Document Type
Article
Abstract
Translate Background: KRAS mutations have a significant role in the consecutive activation of RAS-RAF-MEK-ERK pathway in colorectal cancer. Approximately 30-35% of sporadic colorectal cancers have KRAS mutation. While the predictive role of KRAS is commonly accepted at the present time, its prognostic role and association with different clinical and histopathological properties are currently unclear and inconsistent. The intent of this study, has been to evaluate the associations between KRAS gene mutations and clinicopathological features and survival times in Turkish colorectal cancer patients.
Materials and Methods: In this study, the file records of 115 metastatic colorectal cancer patients who applied to the Department of Medical Oncology between 2000 and 2011 were monitored; data on clinicopathological features and survival times were collected. DNA-sequencing method with PCR amplification from archival paraffin blocks were used for KRAS mutation status analysis. The associations between KRAS mutation status and clinicopathological features and survival times were compared statistically.
Results: While a significant association hadbeen determined between KRAS mutation status and tumor localization, there was no determined significant association with other clinicopathological properties. Similarly, there was no association between KRAS mutation status and survival parameters.
Conclusions: As a result, the effect of KRAS mutation status on clinicopathological features, survival time and prognosis is unclear.
Keywords
Author Keywords
Clinicopathological properties KRAS metastatic colorectal cancer prognosis
The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG)
By
Tanriverdi, O (Tanriverdi, Ozgur) [1] ; Menekse, S (Menekse, Serkan) [2] ; Teker, F (Teker, Fatih) [3] ; Oktay, E (Oktay, Esin) [4] ; Pilanci, KN (Pilanci, Kezban Nur) [5] ; Gunaldi, M (Gunaldi, Meral) [6] ; Kocar, M (Kocar, Muharrem) [7] ; Kacan, T (Kacan, Turgut) [8] ; Bahceci, A (Bahceci, Aykut) [8] ; Avci, N (Avci, Nilufer) [9] ;
(provided by Clarivate)
Source
Volume
21
Issue
4
Page
840-850
Published
JUL-AUG 2016
Indexed
2016-10-05
Document Type
Article
Abstract
Translate Purpose: To determine the predictive value of the mean platelet volume (MPV) and the MPV/platelet count ratio on the development of isolated bone metastasis in patients with breast cancer.
Methods: A total of 121 previously untreated female patients with isolated bone metastases from breast cancer (group 1) were included in this retrospective cohort study. The patients enrolled in this study had similar age, biological subtypes, and duration of follow-up after diagnosis. Group 1 was compared with both 71 previously untreated women with breast cancer with no metastases at all (group 2) and 39 healthy women (group 3). Demographic data, laboratory tests and histological features of all of the patients in groups 1 and 2 were recorded and the study variables from each of the three groups were compared.
Results: In group 1, the cut-off value (9.2 fL) for the MPV was determined and patients were stratified into 4 subgroups. The MPV was higher in group 1 than in either group 2 or group 3. Group 1 patients had a MPV of 8.8 +/- 3.1 fL (mean 5.1, range: 6.1-15.6) and the cut-off value for MPV was 9.2fl. For patients in group 1, the MPV distribution was stratified into 4 groups as follows: group A included MPV values <6.08 fL, in group B values ranged from 6.09 to 8.46 fL, group C included values from 8.47 to 10.05 fL, and group D included patients with MPV values >10.06fL. MPV and the presence of lymphovascular invasion were found to be independent risk factors for the development of isolated bone metastases.
Conclusion: We concluded that MPV can be used to predict the development of isolated bone metastases.
Keywords
Author Keywords
bone metastases breast cancer mean platelet volume platelet count
Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab
By
Tonyali, O (Tonyali, Onder) [1] ; Coskun, U (Coskun, Ugur) [2] ; Yuksel, S (Yuksel, Sinemis) [3] ; Inanc, M (Inanc, Mevlude) [4] ; Bal, O (Bal, Oznur) [5] ; Akman, T (Akman, Tulay) [6] ; Yazilitas, D (Yazilitas, Dogan) [7] ; Ulas, A (Ulas, Arife) [8] ; Kucukoner, M (Kucukoner, Mehmet) [9] ; Aksoy, A (Aksoy, Asude) [10] ;
Group Author
ASMO (ASMO)
(provided by Clarivate)
Source
Volume
25
Page
22-26
DOI
10.1016/j.breast.2015.11.006
Published
FEB 2016
Indexed
2016-02-10
Document Type
Article
Abstract
Translate Purpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.
Methods: Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively.
Results: Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence.
Conclusions: In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence. (C) 2015 Elsevier Ltd. All rights reserved.
Keywords
Author Keywords
Breast cancer Adjuvant therapy Trastuzumab Brain metastasis
The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy
By
Akman, T (Akman, Tulay) [1] ; Oztop, I (Oztop, Ilhan) [2] ; Baskin, Y (Baskin, Yasemin) [3] ; Akbarpour, M (Akbarpour, Mahdi) [3] ; Unal, OU (Unal, Olcun Umit) [4] ; Oflazoglu, U (Oflazoglu, Utku) [2] ; Ellidokuz, H (Ellidokuz, Hulya) [5]
(provided by Clarivate)
Source
Volume
32
Issue
1
DOI
10.1007/s12032-014-0440-7
Article Number
440
Published
JAN 2015
Indexed
2015-02-25
Document Type
Article
Abstract
Translate Data regarding the prognostic importance of BRAFV600 tumor mutations in high-risk, non-metastatic, stage 2 and 3 malignant melanoma (MM) patients are controversial. There is not sufficient information in the medical literature regarding the reliability of BRAF mutations as a predictive factor in prognosis and adjuvant treatment decision issues in this patient group. The data of 50 operated high-risk, non-metastatic, stage 2B/2C and 3 MM patients who received high-dose interferon alfa-2b therapy were evaluated retrospectively. BRAF mutations were analyzed by using microarray-based molecular methods. The associations between BRAF mutations and both clinicopathological characteristics and survival were assessed. Of the 50 patients, 52 % was female and 48 % was male, and the median age was 51.5 years. Twenty-three (46 %) and 27 (54 %) patients had stage 2B/2C and stage 3 disease, respectively. BRAF mutation was detected in 21 patients. The median overall survival (OS) was 58.1 months, whereas the median disease-free survival (DFS) was 22.7 months. When the OS and DFS were compared according to the BRAF mutation status, no difference was detected between the two groups. BRAF mutations were detected more frequently in tumors with mitosis and ulceration; however, no statistically significant difference was observed in other clinicopathological parameters. In conclusion, it is not appropriate to use BRAF mutations as a prognostic and predictive marker for selecting the treatment and assessing its outcomes in patients with early stage, high-risk MM.
Keywords
Author Keywords
BRAFA djuvant high-dose interferon Survival Clinicopathological features
Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology)
By
Kaplan, MA (Kaplan, Muhammet A.) [1] ; Arslan, UY (Arslan, Ulku Y.) [2] ; Isikdogan, A (Isikdogan, Abdurrahman) [1] ; Dane, F (Dane, Faysal) [3] ; Oksuzoglu, B (Oksuzoglu, Berna) [2] ; Inanc, M (Inanc, Mevlude) [4] ; Akman, T (Akman, Tulay) [5] ; Kucukoner, M (Kucukoner, Mehmet) [1] ; Cinkir, HY (Cinkir, Havva Y.) [2] ; Rzazade, R (Rzazade, Rashad) [3] ;
(provided by Clarivate)
Source
Volume
11
Issue
4
Page
248-252
DOI
10.1159/000448186
Published
2016
Indexed
2016-10-05
Document Type
Article
Abstract
Translate Purpose: The aim of the study was to investigate the association between the molecular subtypes and patterns of relapse in breast cancer patients who had undergone curative surgery. Methods: We retrospectively evaluated 1,350 breast cancer patients with relapses after curative surgery between 1998 and 2012 from referral centers in Turkey. Patients were divided into 4 biological subtypes according to immunohistochennistry and grade: triple negative, HER2 overexpressing, luminal A and luminal B. Results: The percentages of patients with luminal A, lumina! B, HER2-overexpressing, and triple-negative breast cancer were 32.9% (n = 444), 34.9% (n = 471), 12.0% (n = 162), and 20.2% (n = 273), respectively. The distribution of metastases differed among the subgroups: bone (66.2% and 53.9% in lumina! A and B vs. 38.9% in HER2-overexpressing and 45.1% in triple negative, p < 0.001), liver (40.1% in HER2-overexpressing vs. 24.5% in lumina! A, 33.5% in luminal B, and 27.5% in triple negative, p < 0.001), lung (41.4% in triple negative and 35.2% in HER2-overexpressing vs. 30.2% and 30.6% in luminal A and B, p = 0.008) and brain (25.3% in HER2overexpressing and 23.1% in triple negative vs. 10.1% and 15.1% in lumina! A and B, p < 0.001). Conclusions: Organ -specific metastasis may depend on the molecular subtype of breast cancer. Tailored strategies against distant metastasis concerning the molecular subtypes in breast cancer should be considered. (C) 2016 S. Karger GmbH, Freiburg.
Keywords
Author Keywords
Breast cancer Relapse pattern Molecular subtype
Erythrocyte Deformability and Oxidative Stress in Inflammatory Bowel Disease
By
Akman, T (Akman, Tulay) [1] ; Akarsu, M (Akarsu, Mesut) [2] ; Akpinar, H (Akpinar, Hale) [2] ; Resmi, H (Resmi, Halil) [3] ; Sezer, E (Sezer, Ebru) [4]
(provided by Clarivate)
Source
DIGESTIVE DISEASES AND SCIENCES
Volume
57
Issue
2
Page
458-464
DOI
10.1007/s10620-011-1882-9
Published
FEB 2012
Indexed
2012-02-28
Document Type
Article
Abstract
Translate Oxidative stress and reduced microvascular flow are important factors in the pathogenesis of inflammatory bowel disease (IBD). The increased oxidative stress reduces the eriytrocyte deformability. However, in IBD, there are no studies in the literature which evaluate erythrocyte deformability.
In our study, we investigated the effect of oxidative stress and erythrocyte deformability in IBD.
Forty-three patients with active IBD, 48 patients with inactive IBD and 45 healthy controls were included. The erytrocyte deformability, malonyldialdehyde levels, glutation peroxidase and sulfhydryl levels were measured in peripheral venous blood samples.
Erytrocyte malonyldialdehyde levels in both active and inactive IBD were significantly increased compared with control groups. Plasma glutation peroxidase levels did not show statistically significant difference between all groups. The decreased plasma sulfhydryl levels in active IBD were statistically significant compared with both the inactive IBD and the control group, but plasma sulfhydryl levels in inactive IBD group did not show statistically significant differences when compared with the control group. Elongation index values in both active and inactive IBD increased significantly compared with the control group. Statistically significant correlations were not found between the elongation index and glutation peroxidase, malonyldialdehyde, sulfhydryl levels in all groups.
Our study is the first to evaluate the erythrocyte deformability in IBD. In our study, increased erytrocyte malonyldialdehyde levels and decreased plasma sulfhydryl levels manifested the role of oxidative stress in the pathogenesis of the disease. It is thought that the increased erythrocyte malonyldialdehyde values cause the reduction in erythrocyte deformability.
Keywords
Author Keywords
Erythrocyte deformability Oxidative stress Crohn disease Ulcerative colitis
Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors
By
Diniz, G (Diniz, Gulden) [1] ; Karadeniz, T (Karadeniz, Tugba) [1] ; Sayhan, S (Sayhan, Sevil) [1] ; Akata, T (Akata, Talya) [1] ; Aydiner, F (Aydiner, Fatma) [1] ; Ayaz, D (Ayaz, Duygu) [1] ; Kahraman, DS (Kahraman, Dudu Solakoglu) [1] ; Akman, T (Akman, Tulay) [2]
(provided by Clarivate)
Source
Volume
88
Issue
2
Page
51-55
DOI
10.5603/GP.a2017.0011
Published
2017
Indexed
2017-03-29
Document Type
Article
Abstract
Translate Objectives: Human Epididymal Secretory Protein 4 was firstly described as an epididymis-specific protein but more recently it has been demonstrated to be a putative serum tumor marker for different malignancies, especially ovarian epithelial cancers. The aim of this study is to investigate the association between tissue Human Epididymal Secretory Protein 4 expression and the clinicopathological features of uterine cervical tumors.
Material and methods: This retrospective study was designed to evaluate the differences of tissue expressions of Human Epididymal Secretory Protein 4 protein in a spectrum of cervical neoplasms. One hundred and seven patients recently diagnosed as having cervical intraepithelial neoplasm or invasive squamous cell carcinoma, adenosquamous carcinoma and adenocarcinoma based on pathology databases.
Results: Decreased or negative Human Epididymal Secretory Protein 4 expressions were determined in both normal cervical epithelia and in intraepithelial carcinomas, while increased HE4 expression was observed in invasive tumors.
Conclusions: This study demonstrated that altered expression of Human Epididymal Secretory Protein 4 may involve in tumorigenesis in the uterine cervix. Our findings also suggested the presence of a correlation between Human Epididymal Secretory Protein 4 expression and the invasive potential of uterine tumors. Therefore it may be thought that the tissue expression of HE4 can be used to differentiate high grade intraepithelial tumors from carcinomas.
Keywords
Author Keywords
uterine cervix Human Epididymal Secretory Protein 4HE4 squamous cell carcinoma
Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix
By
Kahraman, DS (Kahraman, Dudu Solakoglu) [1] ; Diniz, G (Diniz, Gulden) [1] ; Sayhan, S (Sayhan, Sevil) [1] ; Ayaz, D (Ayaz, Duygu) [1] ; Uncel, M (Uncel, Melek) [1] ; Karadeniz, T (Karadeniz, Tugba) [1] ; Akman, T (Akman, Tulay) [2] ; Ozdemir, A (Ozdemir, Aykut) [3]
(provided by Clarivate)
Source
Volume
123
Issue
10
Page
847-850
DOI
10.1111/apm.12435
Published
OCT 2015
Indexed
2015-10-22
Document Type
Article
Abstract
Translate AT-rich interactive domain 1A (ARID1A) is a tumor suppressor gene involved in chromatin remodeling which encodes ARID1A (BAF250a) protein. Recent studies have shown the loss of ARID1A expression in several types of tumors. This retrospective study was designed to evaluate the differences in tissue expressions of ARID1A in a spectrum of cervical neoplasms. Cervical intraepithelial neoplasms, invasive squamous or adenosquamous carcinomas were identified in 100 patients recently diagnosed as cervical neoplasms based on pathology databases. In this series, there were 29 low- and 29 high-grade cervical intraepithelial neoplasms, 27 squamous cell carcinomas, and 15 adenosquamous carcinomas. Mean age of the patients was 47.8 +/- 13years (20-80years). It was determined that the expression of ARID1A was statistically significantly down-regulated in adenosquamous carcinomas when compared with non-invasive or invasive squamous cell carcinomas (p=0.015). Lower levels of the ARID1A expression were detected in cases with adenosquamous carcinomas (60%), low- or high-grade squamous intraepithelial lesion (SIL) (31%), and squamous cell carcinomas (18.5%). Our findings have demonstrated the presence of a correlation between ARID1A expression and adenomatous differentiation of uterine squamous cell carcinomas. Therefore, ARID1A gene may suggestively have a role in the pathogenesis of cervical adenosquamous carcinomas.
Keywords
Author Keywords
Uterine cervix ARID-1Asquamous cell carcinoma adenosquamous carcinoma
Tumor deposits in gastric carcinomas
By
Ersen, A (Ersen, Ayca) [1] ; Unlu, MS (Unlu, Mehtat S.) [1] ; Akman, T (Akman, Tulay) [2] ; Sagol, O (Sagol, Ozgul) [1] ; Oztop, I (Oztop, Ilhan) [2] ; Atila, K (Atila, Koray) [3] ; Bora, S (Bora, Seymen) [3] ; Ellidokuz, H (Ellidokuz, Huyla) [4] ; Sarioglu, S (Sarioglu, Sulen) [1]
(provided by Clarivate)
Source
PATHOLOGY RESEARCH AND PRACTICE
Volume
210
Issue
9
Page
565-570
DOI
10.1016/j.prp.2014.03.006
Published
2014
Indexed
2014-01-01
Document Type
Article
Abstract
Translate We performed this study to examine the prevalence of tumor deposits (TD) in gastric adenocarcinomas (GACa), and the relevance of their presence, size and type to clinical outcome.
Ninety-six patients, histopathologically diagnosed as GACa following a total/subtotal gastrectomy were included, and clinicopathologic data were recorded.
Due to the statistical analysis, the majority of TD(+) cases were of intestinal type and showed vascular invasion. In these cases, the incidence of local recurrence was significantly higher. The majority of GACa of intestinal type with TD were of high grade and showed vascular invasion. Recurrence and death were more commonly encountered among them. The recurrence-free survival (RFS) was significantly shorter in patients with TDs, which was also confirmed by multivariate analysis, and there was a significant difference between both RFS and overall survival of TD(+) and TD() cases of intestinal type GACa.
In conclusion, in this study, we demonstrate that TDs are not infrequently observed in GACa, they are more commonly associated with the intestinal type and vascular invasive gastric cancers. Our study shows the prognostic impact of TDs, especially regarding the RFS. Therefore, the documentation of TDs might be considered for prospective studies, especially for the intestinal type GACa, a shortcoming of this study. (C) 2014 Elsevier GmbH. All rights reserved.
Keywords
Author Keywords
Tumor deposit Gastric adenocarcinoma Intestinal type Vascular invasion
Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group
By
Tanriverdi, O (Tanriverdi, Ozgur) [1] ; Cokmert, S (Cokmert, Suna) [2] ; Oktay, E (Oktay, Esin) [3] ; Pilanci, KN (Pilanci, Kezban Nur) [4] ; Menekse, S (Menekse, Serkan) [5] ; Kocar, M (Kocar, Muharrem) [6] ; Sen, CA (Sen, Cenk Ahmet) [7] ; Avci, N (Avci, Nilufer) [8] ; Akman, T (Akman, Tulay) [9] ; Ordu, C (Ordu, Cetin) [4] ;
(provided by Clarivate)
Source
Volume
31
Issue
10
DOI
10.1007/s12032-014-0217-z
Article Number
217
Published
OCT 2014
Indexed
2014-10-15
Document Type
Article
Abstract
Translate Non-small cell lung cancer (NSCLC) is one of the most common cancers. Most of the patients are inoperable at the time of diagnosis, and the prognosis is poor. Many prognostic factors have been identified in prior studies. However, it is not clear which factor is more useful. In this study, we investigated whether uric acid, the last breakdown product of purine metabolism in humans, has a prognostic significance in advanced NSCLC. A total of 384 NSCLC patients at stage IIIB/IV and who did not meet exclusion criteria were included in this retrospective cross-sectional study. The patients' serum uric acid levels before first-line chemotherapy and demographic (age, gender, smoking), clinical (performance status, weight loss, disease stage, first-line treatment regimen), laboratory (hemoglobin, lactate dehydrogenase), and histologic (histologic type, tumor grade) characteristics were recorded. First, a cut-off value was determined for serum uric acid level. Then, the patients were stratified into four groups (quartiles) based on their serum uric acid levels. Descriptive statistics, univariate and multivariate analyses, and survival analyses were used. Majority of the patients were males, smokers and metastatic at time of diagnosis and had history of weight loss and adenocarcinoma upon pathological examination. The serum uric acid levels of all patients were determined as 4.9 +/- 2.9 (range 1.9-11.3). The patients were stratified according to quartiles of serum uric acid concentration with cutoff values defined as <3.08 mg/dL (lowest quartile, Group 1), 3.09-5.91 mg/dL (Group 2), 5.92-7.48 mg/dL (Group 3), and >7.49 mg/dL (highest quartile, Group 4). Among the patients who had serum uric acid levels over 7.49, it was observed that those who also had squamous cell carcinoma had a greater rate of brain metastasis, a shorter time lapse until brain metastasis, and lower overall survival rate. It can be assumed that NSCLC patients who had histologically shown squamous cell carcinoma display brain metastasis and poor prognosis. It can be recommended to repeat this study with larger patient series including immunohistochemical, molecular, and wider laboratory investigations.
Keywords
Author Keywords
Non-small cell lung cancer Serum uric acid Prognosis
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology
By
Kaplan, MA (Kaplan, Muhammet Ali) [1] ; Isikdogan, A (Isikdogan, Abdurrahman) [1] ; Koca, D (Koca, Dogan) [2] ; Kucukoner, M (Kucukoner, Mehmet) [1] ; Gumusay, O (Gumusay, Ozge) [3] ; Yildiz, R (Yildiz, Ramazan) [4] ; Dayan, A (Dayan, Adem) [2] ; Demir, L (Demir, Lutfiye) [5] ; Geredeli, C (Geredeli, Caglayan) [6] ; Kocer, M (Kocer, Murat) [7] ;
(provided by Clarivate)
Source
Volume
21
Issue
6
Page
677-683
DOI
10.1007/s12282-013-0441-y
Published
NOV 2014
Indexed
2014-12-03
Document Type
Article
Abstract
Translate In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis.
Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis. Patients who only received trastuzumab-based therapy after the development of brain metastases were accepted as the historic control group for survival analyses (n = 65). Patients who received both drugs consecutively or sequentially were excluded from the analyses (n = 34).
Median age among 46 patients who received lapatinib plus capecitabine therapy was 45 years (27-76), and median time for development of brain metastases was 11.9 months (0-69 months). Twenty-six out of 38 patients who received lapatinib plus capecitabine and had extracranial metastasis showed partial response or stable diseases (68.4 %). Grade 3-4 toxicity was observed in eight patients (17.3 %). Median overall survival (OS) in patients treated with lapatinib plus capecitabine was significantly increased compared to that in patients treated with trastuzumab-based therapy (19.1 vs. 12 months, respectively, p = 0.039). The incidence of cerebral death was slightly decreased in patients who received lapatinib plus capecitabine compared to those who received trastuzumab-based therapy (32 vs. 43.4 %, p = 0.332). In the multivariate analysis, lapatinib plus capecitabine therapy remained an independent positive predictor for survival [odds ratio (OR), 0.57; p = 0.02].
Although this retrospective multicenter study had several limitations, the results suggest that undergoing lapatinib plus capecitabine therapy after the diagnosis of brain metastasis may further improve survival compared to undergoing only trastuzumab-based therapy.
Keywords
Author Keywords
Lapatinib Capecitabine Trastuzumab Brain metastases Breast cancer HER2
The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)
By
Tanriverdi, O (Tanriverdi, Ozgur) [1] ; Kaytan-Saglam, E (Kaytan-Saglam, Esra) [2] ; Ulger, S (Ulger, Sukran) [3] ; Bayoglu, IV (Bayoglu, Ibrahim Vedat) [4] ; Turker, I (Turker, Ibrahim) [5] ; Ozturk-Topcu, T (Ozturk-Topcu, Turkan) [6] ; Cokmert, S (Cokmert, Suna) [7] ; Turhal, S (Turhal, Serdar) [8] ; Oktay, E (Oktay, Esin) [9] ; Karabulut, B (Karabulut, Bulent) [10] ;
(provided by Clarivate)
Source
Volume
31
Issue
9
DOI
10.1007/s12032-014-0152-z
Article Number
152
Published
SEP 2014
Indexed
2014-09-01
Document Type
Article
Abstract
Translate Brain metastasis in colorectal cancer is highly rare. In the present study, we aimed to determine the frequency of brain metastasis in colorectal cancer patients and to establish prognostic characteristics of colorectal cancer patients with brain metastasis. In this cross-sectional study, the medical files of colorectal cancer patients with brain metastases who were definitely diagnosed by histopathologically were retrospectively reviewed. Brain metastasis was detected in 2.7 % (n = 133) of 4,864 colorectal cancer patients. The majority of cases were male (53 %), older than 65 years (59 %), with rectum cancer (56 %), a poorly differentiated tumor (70 %); had adenocarcinoma histology (97 %), and metachronous metastasis (86 %); received chemotherapy at least once for metastatic disease before brain metastasis developed (72 %), had progression with lung metastasis before (51 %), and 26 % (n = 31) of patients with extracranial disease at time the diagnosis of brain metastasis had both lung and bone metastases. The mean follow-up duration was 51 months (range 5-92), and the mean survival was 25.8 months (95 % CI 20.4-29.3). Overall survival rates were 81 % in the first year, 42.3 % in the third year, and 15.7 % in the fifth year. In multiple variable analysis, the most important independent risk factor for overall survival was determined as the presence of lung metastasis (HR 1.43, 95 % CI 1.27-4.14; P = 0.012). Brain metastasis develops late in the period of colorectal cancer and prognosis in these patients is poor. However, early screening of brain metastases in patients with lung metastasis may improve survival outcomes with new treatment modalities.
Keywords
Author Keywords
Colorectal cancer Brain metastasis Prognosis
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
By
Yildiz, I (Yildiz, Ibrahim) [1] ; Bilici, A (Bilici, Ahmet) [2] ; Karadurmus, N (Karadurmus, Nuri) [3] ; Ozer, L (Ozer, Leyla) [1] ; Tural, D (Tural, Deniz) [4] ; Kaplan, MA (Kaplan, Mehmet A.) [5] ; Akman, T (Akman, Tulay) [6] ; Bayoglu, IV (Bayoglu, Ibrahim, V) [7] ; Uysal, M (Uysal, Mukremin) [8] ; Yildiz, Y (Yildiz, Yasar) [9] ;
(provided by Clarivate)
Source
Volume
104
Issue
6
Page
444-450
DOI
10.5301/tj.5000635
Published
DEC 2018
Indexed
2019-01-11
Document Type
Article
Abstract
Translate Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.
Keywords
Author Keywords
Brain metastasis Prognostic factor Renal cell carcinoma Survival Targeted therapy
Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects
By
Akman, T (Akman, Tulay) [1] , [2] ; Erbas, O (Erbas, Oytun) [3] ; Akman, L (Akman, Levent) [4] , [5] ; Yilmaz, AU (Yilmaz, Ahmet U.) [6]
(provided by Clarivate)
Source
ARQUIVOS BRASILEIROS DE CARDIOLOGIA
Volume
103
Issue
5
Page
403-409
DOI
10.5935/abc.20140138
Published
NOV 2014
Indexed
2015-02-25
Document Type
Article
Abstract
Translate Background: Pazopanib (PZP) may induce prolonged cardiac repolarization and proarrhythmic effects, similarly to other tyrosine kinase inhibitors. Objectives: To demonstrate PZP-induced prolonged cardiac repolarization and proarrhythmic electrophysiological effects and to investigate possible preventive effects of metoprolol and diltiazem on ECG changes (prolonged QT) in an experimental rat model.
Methods: Twenty-four Sprague-Dawley adult male rats were randomly assigned to 4 groups (n = 6). The first group (normal group) received 4 mL of tap water and the other groups received 100 mg/kg of PZP (Votrient (R) tablet) perorally, via orogastric tubes. After 3 hours, the following solutions were intraperitoneally administered to the animals: physiological saline solution (SP), to the normal group and to the second group (control-PZP+SP group); 1 mg/kg metoprolol (Beloc, Ampule, AstraZeneca), to the third group (PZP+metoprolol group); and 1 mg/kg diltiazem (Diltiazem, Mustafa Nevzat), to the fourth group (PZP+diltiazem group). One hour after, and under anesthesia, QTc was calculated by recording ECG on lead I.
Results: The mean QTc interval values were as follows: normal group, 99.93 +/- 3.62 ms; control-PZP+SP group, 131.23 +/- 12.21 ms; PZP+metoprolol group, 89.36 +/- 3.61 ms; and PZP+diltiazem group, 88.86 +/- 4.04 ms. Both PZP+metoprolol and PZP+diltiazem groups had significantly shorter QTc intervals compared to the control-PZP+SP group (p < 0.001).
Conclusion: Both metoprolol and diltiazem prevented PZP-induced QT interval prolongation. These drugs may provide a promising prophylactic strategy for the prolonged QTc interval associated with tyrosine kinase inhibitor use.
Keywords
Author Keywords
Arrhythmias, Cardiac / therapy Pyrimidines / adverse effects Heart Conduction System /
Oxytocin Improves Follicular Reserve in a Cisplatin-Induced Gonadotoxicity Model in Rats
By
Erbas, O (Erbas, Oytun) [1] ; Akman, L (Akman, Levent) [2] ; Yavasoglu, A (Yavasoglu, Altug) [3] ; Terek, MC (Terek, Mustafa Cosan) [2] ; Akman, T (Akman, Tulay) [4] ; Taskiran, D (Taskiran, Dilek) [1]
(provided by Clarivate)
Source
Volume
2014
DOI
10.1155/2014/703691
Article Number
703691
Published
2014
Indexed
2014-01-01
Document Type
Article
Abstract
Translate Cisplatin (CP), an antitumor agent, has been shown to cause ovarian injury and dysfunction in both animal and human studies. The present study was conducted to investigate the protective effect of oxytocin (OT) on CP-induced ovarian toxicity in rats. Twenty-one adult female rats were included in the study. Fourteen rats were administered intraperitoneally CP (2mg/kg/day) twice a week for 5 weeks. Control group (n = 7) did not receive any treatment. Following treatment, CP-received rats were randomly divided into two groups and treated with either saline (1 mL/kg/day, n = 7) or OT (160 mu g/kg/day, n = 7) for 5 weeks. Then, ovarian toxicity and effects of OT were evaluated by histomorphological and biochemical analysis. Our findings revealed a significant reduction in the number of follicles at each grade in saline-treated group. AMH level was significantly lower in saline group compared to control (P < 0.0005). OT treatment significantly attenuated CP toxicity in ovaries and increased AMH levels compared to saline group (P < 0.005). Also, administration of OT lessened lipid peroxidation and prevented glutathione depletion in CP-treated rats (P < 0.05). These results indicated that OT could lessen the CP-induced ovarian damage and improve follicular reserve by preventing oxidative damage.
Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study
By
Urun, Y (Urun, Yuksel) [1] ; Yasar, HA (Yasar, H. Arzu) [1] ; Turna, H (Turna, Hande) [2] ; Esin, E (Esin, Ece) [3] ; Sedef, AM (Sedef, A. Murat) [4] ; Alkan, A (Alkan, Ali) [5] ; Oksuzoglu, B (Oksuzoglu, Berna) [3] ; Ozdemir, N (Ozdemir, Nuriye) [6] ; Sendur, MAN (Sendur, M. A. Nahit) [7] ; Sezer, A (Sezer, Ahmet) [4] ;
(provided by Clarivate)
Source
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume
25
Issue
7
Page
1658-1664
DOI
10.1177/1078155218805539
Published
OCT 2019
Indexed
2019-10-01
Document Type
Article
Jump to
Abstract
Translate Purpose Studies in the last decade show survival improvement with checkpoint blocker therapy in patients with metastatic malign melanoma. Our purpose was to define the efficacy of ipilimumab according to the patient's baseline characteristics including absolute lymphocytes count. Methods We collected the data of 97 patients with advanced malign melanoma treated with ipilimumab (3 mg/kg, q3w) retrospectively. Log-rank test was used to analyze the univariate effects of patient's characteristics (age, gender, metastatic sites, ECOG PS, type of melanoma, lactic dehydrogenase levels, anemia, lymphocytes (L), neutrophils (N), N/L ratio), c-kit and BRAF status. Survival analyses were estimated with Kaplan-Meier method. Cox regression analysis was used to assess the possible factors identified with log-rank test. Results The median age was 58, and 58% were male and 90% of patients had at least one prior systemic therapy. The median survival was 9.7 months for all patients; and the 12- and 24-month survival rates were 43% and 19%, respectively. Absolute lymphocytes count, lactic dehydrogenase level, bone metastasis, the number of metastatic sites, and RECIST response were significantly related to survival. After Cox regression analysis, RECIST response (complete or partial response), absolute lymphocytes count (more than 1500/mm(3)) and the number of metastatic sites (less than three sites) remained as significant independent prognostic factors for longer survival. Conclusion Ipilimumab improved survival of patients with metastatic malign melanoma. However, patients with fewer metastatic sites and higher absolute lymphocytes count have a significantly better benefit. To determine if these markers could be used to direct patient therapy, further validation analysis is needed.
Keywords
Author Keywords
Ipilimumab melanoma prognostic factors absolute lymphocytes count
The Role of 18F-FDG PET/CT in the Evaluation of Gastric Cancer Recurrence
By
Cayvarli, H (Cayvarli, Hakan) [1] ; Bekis, R (Bekis, Recep) [2] ; Akman, T (Akman, Tulay) [3] ; Altun, D (Altun, Deniz) [4]
(provided by Clarivate)
Source
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
Volume
23
Issue
3
Page
76-83
DOI
10.4274/mirt.83803
Published
OCT 2014
Indexed
2014-10-01
Document Type
Article
Abstract
Translate Objective: F-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been widely used for staging, re-staging and for monitoring therapy-induced changes and response to therapy in patients with various types of cancer, but its utilization for gastric cancer has been limited. This study aimed to assess the diagnostic performance of 18F-FDG PET/CT for detecting recurrence in gastric cancer patients with radiologic or clinical suspicion of recurrence and its clinical impact on making decision.
Methods: We performed a retrospective review of 130 consecutive patients who underwent PET/CT scans for post-treatment surveillance of gastric cancer between January 2008 and March 2012. The mean time between the initial diagnosis of gastric cancer and PET/CT studies was 44 weeks with a median of 18 weeks. The number and site of positive FDG uptake were analyzed and correlated with the final diagnosis by calculating the diagnostic values. We evaluated the diagnostic accuracy of PET/CT for detecting the recurrence in terms of whether or not histology had been SRC/musinous adenocarcinoma. The changes in the clinical management of patients were also evaluated according to the results of PET/CT.
Results: Of all 130 patients, 91 patients were confirmed to have true recurrence. The sensitivity, specificity, positive predictive value, negative predictive value and the accuracy of PET/CT for diagnosing true recurrence on a per-person basis were 91.2%, 61.5%, 84.6%, 75.0% and 82.3% respectively. Final diagnoses were confirmed histopathologically in 59 (45.4%) of 130 patients and by clinical and radiological follow-up in the remaining 71 (54.6%) patients. In the subgroup with SRC/mucinous adenocarcinoma differentiation of the primary tumor, there was no statistically significant difference in terms of diagnostic accuracy of PET/CT on a per-person basis. In addition, PET/CT results changed the patients' management in 20 (15%) cases.
Conclusions: 18F-FDG PET/CT can provide useful information in discriminating true recurrence in patients with suspected gastric cancer recurrence and may have significant impact on clinical decisions/patient management in a considerable percentage of patients.
Keywords
Author Keywords
Gastric cancer positron-emission tomography 18F-FDG disease management
Classic Kaposi's sarcoma: A review of 156 cases
By
Cetin, B (Cetin, Bulent) [1] , [7] ; Aktas, B (Aktas, Bilge) [2] ; Bal, O (Bal, Oznur) [3] ; Algin, E (Algin, Efnan) [3] ; Akman, T (Akman, Tulay) [4] ; Koral, L (Koral, Lokman) [5] ; Kaplan, MA (Kaplan, Mehmet Ali) [8] ; Demirci, U (Demirci, Umut) [6] ; Uncu, D (Uncu, Dogan) [3] ; Ozet, A (Ozet, Ahmet) [9]
(provided by Clarivate)
Source
Volume
36
Issue
4
Page
185-189
DOI
10.1016/j.dsi.2018.06.005
Published
DEC 2018
Indexed
2018-12-28
Document Type
Review
Abstract
Translate Background: Kaposi's sarcoma (KS) is a reactive, multifocal, multicentric, angiogenic neoplastic proliferation that is thought to originate from endothelial cells that are infected with human herpesvirus-8 (HHV-8). This report examines a cohort of patients with classic Kaposi's sarcoma (KS) evaluated at the national institute of oncology over the 13-year period.
Methods: A retrospective analysis of 156 patients with classic KS, between January 2000 and November 2013, was performed. This study focused on the clinical presentation, staging, diagnosis, and treatment of classic KS.
Results: One hundred fifty-six patients (median age 69 and 115 male) were enrolled into the study. Median age at diagnosis was 69 (range: 32e95 years). Male/female ratio was 2.80. The most common location was the lower limbs. There were 75 stage I patients (48.1%), 8 stage II patients (22.4%), 31 stage III patients (19.9%) and 15 stage IV patients (9.6%). Surgery was the most common local treatment method (43%). 44 patients (28.2%) received radiotherapy (RT) at diagnosis. Cytotoxic treatment with chemotherapy or interferon-a was administered in 57 patients. Visceral involvement was observed in 10 patients (lung: nine patients, liver: one patient) and bone metastasis occurred in two patients at relapse.
Conclusion: This study is one of the largest reported series. Further studies are required and it will be important to standardize the assessment of disease activity and clinical response. Copyright (C) 2018, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC.
Keywords
Classic Kaposi's sarcoma Radiotherapy Surgery Chemotherapy
Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study
By
Erbas, O (Erbas, Oytun) [1] ; Pala, HG (Pala, Halil Gursoy) [2] ; Pala, EE (Pala, Emel Ebru) [3] ; Ulkumen, BA (Ulkumen, Burcu Artunc) [2] ; Akman, L (Akman, Levent) [4] ; Akman, T (Akman, Tulay) [5] ; Oltulu, F (Oltulu, Fatih) [6] ; Aktug, H (Aktug, Huseyhz) [6] ; Yavasoglu, A (Yavasoglu, Altug) [6]
(provided by Clarivate)
Source
Volume
31
Issue
5
Page
388-391
DOI
10.3109/09513590.2015.1005593
Published
MAY 2015
Indexed
2015-08-26
Document Type
Article
Abstract
Translate The aim of our study is to investigate the effect of sunitinib on diabetes mellitus related-ovarian injury and fibrosis in rat models. An experimental diabetes mellitus model was created in 16 rats, and eight rats with normal blood glucose levels were included in control group (Group-1). The diabetic rats were divided into two groups:diabetic control group (water given) - Group-2 and sunitinib treatment group - Group-3. After four weeks, bilateral oophorectomy was performed and ovaries were examined histologically. The groups were compared by Student's t-test, analysis of variance (ANOVA) and Mann Whitney's U-test. There was a significant increase in no-medication (water given) diabetic rat's ovary (Group-2) in terms of follicular degeneration, stromal degeneration, stromal fibrosis and NF-kappaB immune-expression compared with control group normal rats' ovary (Group-1) (p < 0.0001). Stromal degeneration (p = 0.04), stromal fibrosis (p = 0.01), follicular degeneration (p = 0.02), NF-kappaB immune-expression (p = 0.001) significantly decreased in sunitinib-treated diabetic rat's ovary (Group-3) when compared with no-medication (water given) diabetic rat's ovary (Group-2) (p < 0.05). When we used sunitinib in the treatment of diabetic rats, ovarian injury, fibrosis and NF-kappaB immunoexpression decreased significantly. The effects of sunitinib in rat models give hope to the improved treatment of premature ovarian failure due to diabetes mellitus in humans.
Keywords
Author Keywords
Advanced glication end products diabetes mellitus NF-kappaB premature ovarian failure receptor
Relationship between Epidermal Growth Factor Receptor Gene Mutations and Clinicopathological Features in Patients with Non-Small Cell Lung Cancer in Western Turkey
By
Unal, OU (Unal, Olcun Umit) [1] ; Oztop, I (Oztop, Ilhan) [1] ; Calibasi, G (Calibasi, Gizem) [2] ; Baskin, Y (Baskin, Yasemin) [2] ; Koca, D (Koca, Dogan) [4] ; Demir, N (Demir, Necla) [1] ; Akman, T (Akman, Tulay) [1] ; Ellidokuz, H (Ellidokuz, Hulya) [2] ; Yilmaz, AU (Yilmaz, Ahmet Ugur) [3]
(provided by Clarivate)
Source
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
Volume
14
Issue
6
Page
3705-3709
DOI
10.7314/APJCP.2013.14.6.3705
Published
2013
Indexed
2014-03-19
Document Type
Article
Abstract
Translate Background: To investigate epidermal growth factor receptor (EGFR) gene mutations in patients with non-small cell lung cancer (NSCLC) and to analyze any relationship with clinicopathological features and prognosis. Materials and Methods: EGFR gene exons 18-21 in 48 specimens of paraffin-embedded tumor tissue from NSCLC patients were amplified by PCR, followed by direct sequencing and analysis of links to clinicopathological features and prognosis. Results: EGFR mutations were detected in 18 of 48 (42.6%) patients with NSCLC. There were 9 cases of mutations in exon 20, 7 in exon 19 and 2 in exon 21. Mutations were more frequently observed in women (5/7 pts, 71.4%) than in men (13/41 pts, 31.7%) (p=0.086) and in non-smokers (5/5 pts, 100%) than smokers (13/43 pts, 30.2%). There was negative correlation of EGFR mutations with smoking status (p=0.005). EGFR mutations were more frequently observed with adenocarcinoma histology (13/32 pts, 40.6%) than in other types (5/16 pts, 31.3%) (p=0.527). The patients with EGFR mutations had better survival than those with wild-type EGFR (p=0.08). There was no association of EGFR mutations with metastatic spread. Conclusions: EGFR mutations in NSCLC were here demonstrated more frequently in females, non-smokers and adenocarcinoma histology in the western region of Turkey. Patients with EGFR mutations have a better prognosis.
Keywords
Author Keywords
EGFR mutationsnon small cell lung cancer clinical features Western Turkey,
Perspectives and practical applications of medical oncologists on defensive medicine (SYSIPHUS study): a study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)
By
Tanriverdi, O (Tanriverdi, Ozgur) [1] ; Cay-Senler, F (Cay-Senler, Filiz) [2] ; Yavuzsen, T (Yavuzsen, Tugba) [3] ; Turhal, S (Turhal, Serdar) [4] ; Akman, T (Akman, Tulay) [5] ; Komurcu, S (Komurcu, Seref) [6] ; Cehreli, R (Cehreli, Ruksan) [7] ; Ozyilkan, O (Ozyilkan, Ozgur) [8]
(provided by Clarivate)
Source
Volume
32
Issue
4
DOI
10.1007/s12032-015-0555-5
Article Number
106
Published
APR 2015
Indexed
2015-04-15
Document Type
Article
Abstract
Translate Defensive medicine occasionally indulges unnecessary treatment requests to defend against lawsuits for medical errors and the use of unapproved medical applications. This study determines the attitudes and orientations of medical oncologists on defensive medicine. A cross-sectional survey was sent by e-mail to medical oncologists. The survey was designed to determine the participants' demographic characteristics and defensive medicine practices. The survey measured the attitudes about defensive medicine practices of the oncologists based on a five-point Likert scale (never, rarely, sometimes, often, and always). One hundred and forty-six of a total of 402 physicians serving in oncology were fully filled, and the rate of return invitation was 36 %. The majority of participants were male, with a duration of between 7 and 9 years of work as university hospital officials, and the mean age was 46 +/- 9 (years). International guidelines were followed in the most common is NCCN, and the majority of respondents felt that the application of these guidelines improves their defensive medicine. All participants of defensive medicine who stand on the basis of the definition were found to be more afraid of complaints by patients' relatives. Physicians of 45 % was noted that applying defensive medicine. Among the participants were the most frequent checkups of positive defensive approach is defined as increasing or shortening the follow-up period, while avoiding high-risk patients were detected as described in the definition of negative defensive medicine. Both professional groups in both the positive and negative defensive medicine approach defensive medicine approach, academic tasks, work experience and job time, there was a significant correlation between the location. Made in single-and multivariable analyses, positions were identified both positive and negative defensive medicine is an independent risk factor for direction. Improving the working conditions of young physicians to protect against medical error may require additional educational opportunities.
Keywords
Author Keywords
Defensive medicine Medical oncology Malpractice
Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology
By
Gumusay, O (Gumusay, Ozge) [1] ; Coskun, U (Coskun, Ugur) [1] ; Akman, T (Akman, Tulay) [2] ; Ekinci, AS (Ekinci, Ahmet Siyar) [3] ; Kocar, M (Kocar, Muharrem) [4] ; Erceleb, ÖB (Erceleb, Ozlem Balvan) [5] ; Yazici, O (Yazici, Ozan) [6] ; Kaplan, MA (Kaplan, Mehmet Ali) [7] ; Berk, V (Berk, Veli) [8] ; Cetin, B (Cetin, Bulent) [1] ;
(provided by Clarivate)
Source
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume
140
Issue
1
Page
151-157
DOI
10.1007/s00432-013-1553-7
Published
JAN 2014
Indexed
2014-01-29
Document Type
Article
Abstract
Translate The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of < 6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify factors predicting development of BMs and survival.
We performed a retrospective analysis of 470 melanoma patients between 2000 and 2012. The logistic regression analyses were used to identify the clinicopathological features of primary melanoma that are predictive of BMs development and survival after a diagnosis of brain metastases.
There were 52 patients (11.1 %) who developed melanoma BMs during the study period. The analysis of post-BMs with Kaplan-Meier curves has resulted in a median survival rate of 4.1 months (range 2.9-5.1 months). On logistic regression analysis site of the primary tumor on the head and neck (p = 0.002), primary tumor thickness (Breslow > 4 mm) (p = 0.008), ulceration (p = 0.007), and pathologically N2 and N3 diseases (p = 0.001) were found to be significantly associated with the development of BMs. In univariate analysis, tumor thickness and performance status had a significant influence on post-BMs survival. In multivariate analysis, these clinicopathologic factors were not remained as significant predictive factors.
Our results revealed the importance of primary tumor characteristics associated with the development of BMs. Ulceration, primary tumor thickness, anatomic site, and pathologic a parts per thousand yenN2 disease were found to be significant predictors of BMs development.
Keywords
Author Keywords
Melanoma Brain metastases Predictive factors
The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study
By
Kaplan, MA (Kaplan, Muhammet Ali) [1] ; Oruc, Z (Oruc, Zeynep) [1] ; Gumus, M (Gumus, Mahmut) [2] ; Ozaydm, S (Ozaydm, Sukru) [3] ; Elkiran, ET (Elkiran, Emin Tamer) [4] ; Dine, NS (Dine, Nur Sener) [5] ; Sakin, A (Sakin, Abdullah) [6] ; Berk, V (Berk, Veli) [7] ; Akman, T (Akman, Tulay) [8] ; Aytekin, A (Aytekin, Aydin) [9] ;
(provided by Clarivate)
Source
Volume
24
Issue
3
Page
1081-1086
Published
MAY-JUN 2019
Indexed
2019-05-01
Document Type
Article
Abstract
Translate Purpose: To analyze the reliability and the effectiveness of chemotherapy and prognostic factors for survival in patients with HER2 (human epidermal growth receptor 2) negative early-stage breast cancer treated with adjuvant sequential anthracycline-based chemotherapy and paclitaxel.
Methods: This analysis retrospectively evaluated the medical records of 756 HER2 negative early-stage breast cancel-patients who received adjuvant sequential anthracycline-based chemotherapy and weekly paclitaxel in 15 medical oncology centers in Turkey between 2008-2015. Estrogen receptor (ER), progesterone receptor (PR), HER2, age, tumor size and grade, nodal status, perineural and lymphatic invasion, disease-free survival (DFS) and overall survival (OS) were analyzed.
Results: The median patient age was 50 years (22-82). Median follow up period was 46 months (13-82). The rates of recurrence and death detected in this period were 14.8% and 7.4%, respectively.Median OS and PFS were not reached in this period. Five-year DFS and OS rates were 87% and 89%, respectively. Age (OR:0.35, 95%CI 0.12-0.96, p=0.04), PR status (OR:.0.44, 95%CI 0.18-1, p=0.05), lymphatic invasion (OR:.2.6, 95%CI 0.97-7.4, p=0.05) were independent prognostic factors.Most common grade 3-4 toxicides were fatigue (6.7%), neutropenia (1.7%) and nausea (1.3%). Neutropenic fever developed in 1.8% o f the patients and peripheral neuropathy in 16.9%. Dose reduction was necessary for 10%of the patients due to grade 3-4 toxicity, whereas postponement of chemotherapy was neccessary for 7% of the patients.
Conclusions: This multicentric retrospective study confirmed that sequential adjuvant therapy with anthracycline-based chemotherapy and paclitaxel for HER2 negative breast cancer is an effective and reliable regimen.
Keywords
Author Keywords
paclitaxel anthracycline adjuvant breast cancer
Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience
By
Akman, T (Akman, Tulay) [1] ; Oztop, I (Oztop, Ilhan) [2] ; Unek, IT (Unek, Ilkay Tugba) [2] ; Koca, D (Koca, Dogan) [6] ; Unal, OU (Unal, Olcun Umit) [7] ; Salman, T (Salman, Tarik) [4] ; Yavuzsen, T (Yavuzsen, Tugba) [2] ; Yilmaz, AU (Yilmaz, Ahmet Ugur) [5] ; Somali, I (Somali, Isil) [2] ; Demir, N (Demir, Necla) [2] ;
(provided by Clarivate)
Source
Volume
60
Issue
4
Page
228-238
DOI
10.1159/000371838
Published
2014
Indexed
2014-01-01
Document Type
Article
Abstract
Translate Background: Surgical excision constitutes an important part of the treatment of local advanced malignant melanoma. Due to the high recurrence risk, adjuvant high-dose interferon therapy is still the only therapy used in stage IIB and III high-risk melanoma patients. Methods: One hundred two high-risk malignant melanoma patients who received high-dose interferon-alpha-2b therapy were evaluated retrospectively. The clinicopathological features, survival times, and prognostic factors of the patients were determined. Results: The median disease-free and overall survival times were 25.2 and 60.8 months, respectively. Our findings revealed that male gender, advanced disease stage, lymph node involvement, lymphatic invasion, the presence of ulceration, and a high Clark level were significant negative prognostic factors. Conclusion: In light of the favorable survival results obtained in this study, high-dose interferon treatment as adjuvant therapy for high-risk melanoma is still an efficient treatment and its possible side effects can be prevented by taking the necessary precautions. (C) 2015 S. Karger AG, Basel
Keywords
Author Keywords
Interferon Treatment Melanoma Prognostic factors Survival Clinicopathological features
The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and Palliative Care (ALONE Study): A Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)
By
Tanriverdi, O (Tanriverdi, Ozgur) [1] ; Yavuzsen, T (Yavuzsen, Tugba) [2] ; Akman, T (Akman, Tulay) [2] ; Senler, FC (Senler, Filiz Cay) [3] ; Taskoylu, BY (Taskoylu, Burcu Yapar) [4] ; Turhal, S (Turhal, Serdar) [5] ; Komurcu, S (Komurcu, Seref) [6] ; Cehreli, R (Cehreli, Ruksan) [7] ; Yaren, A (Yaren, Arzu) [4] ; Ozyilkan, O (Ozyilkan, Ozgur) [8]
(provided by Clarivate)
Source
Volume
30
Issue
2
Page
253-259
DOI
10.1007/s13187-015-0794-3
Published
JUN 2015
Indexed
2015-05-20
Document Type
Article
Abstract
Translate The aim of our study was to determine the perspective of non-oncologist physicians regarding their attitudes and beliefs associated with palliative care for patients with metastatic cancer. The study was planned as a cross-sectional survey, and non-oncologist physicians were reached via e-mail and social networking sites. The first part of the questionnaire involved demographic properties, the second part inquired as to the perspectives of participants regarding metastatic disease, and the third part was used to determine beliefs and attitudes about palliative care. All of the questions were five-point Likert-type questions. A total of 1734 physicians completed the questionnaire. The majority of participants were general surgeons or internal medicine specialists (21 and 18 %, respectively), were male (61 %), were younger than 50 years of age (54 %), worked in the town center (67 %), had more than 11 years of professional experience (57 %), and worked in a hospital without an active oncology service (86 %). A total of 71 % of participants identified all patients with metastatic cancer as being terminal stage, 62 % were unaware of palliative care techniques, 64 % did not know about common supportive care options, 59 % were against hospice, and 63 % had no opinion on resuscitation. We determined that non-oncologist physicians believed that all patients with metastatic cancer are at the terminal stage and that palliative/supportive care is the oncologist's task. These data suggest that non-oncologist physicians would benefit from additional graduate and postgraduate courses on these topics.
Keywords
Author Keywords
Physicians Palliative care Best supportive care Cancer Metastatic disease Terminal stage cancer
Malign Recurrence of Primary Chest Wall Hemangiopericytoma in the Lung after Four Years: A Case Report and Review of the Literature
By
Akman, T (Akman, Tulay) [1] ; Alacacioglu, A (Alacacioglu, Ahmet) [2] ; Dolek, D (Dolek, Devrim) [3] ; Unek, T (Unek, Tugba) [4] ; Gurel, D (Gurel, Duygu) [5] ; Yilmaz, AU (Yilmaz, Ahmet Ugur) [6] ; Onen, A (Onen, Ahmet) [7]
(provided by Clarivate)
Source
CASE REPORTS IN ONCOLOGICAL MEDICINE
Volume
2014
DOI
10.1155/2014/470268
Article Number
470268
Published
2014
Indexed
2014-01-01
Document Type
Review
Abstract
Translate Hemangiopericytoma (HPC) may develop in every site where the endothelial tissue exits and primarily develops in the skeletalmuscular system or the skin. Adult cases of HPC generally exhibit a benign course. 20-30% of the cases may show a malign course. The tumors that show more than four mitoses, a focal area of necrosis, and increased cellularity on a magnification x10 are considered as malign. In our paper, we presented our case who showed a lung metastasis at the end of 4 years and who developed a pathological fracture of the right humerus at the end of approximately 2 years, because hemangiopericytoma is rarely seen in the chest wall as a primary tumor.
Keywords
Keywords Plus
Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial
By
Yildiz, I (Yildiz, Ibrahim) [1] ; Ekenel, M (Ekenel, Meltem) [2] ; Akman, T (Akman, Tulay) [3] ; Kocar, M (Kocar, Muharrem) [4] ; Uysal, M (Uysal, Mukremin) [5] ; Kanitez, M (Kanitez, Metin) [6] ; Varol, U (Varol, Umut) [1] ; Bayoglu, IV (Bayoglu, Ibrahim Vedat) [1] ; Tural, D (Tural, Deniz) [7] ; Kaplan, MA (Kaplan, Mehmet Ali) [8] ;
(provided by Clarivate)
Source
Volume
34
Issue
8
Page
4329-4334
Published
AUG 2014
Indexed
2014-08-27
Document Type
Article
Abstract
Translate Aim: This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. Patients and Methods: Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. Results: The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. Conclusion: Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients.
Keywords
Author Keywords
Adverse effects metastatic non-clear cell renal cell carcinoma sunitinib
Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study
By
Demirci, A (Demirci, Ayse) [1] ; Alkis, N (Alkis, Necati) [1] ; Dane, F (Dane, Faysal) [2] ; Durnali, A (Durnali, Ayse) [1] ; Yazici, ÖK (Yazici, Omer Kamil) [1] ; Rzayev, R (Rzayev, Rashad) [3] ; Kaya, S (Kaya, Serap) [2] ; Yazilitas, D (Yazilitas, Dogan) [4] ; Inanç, M (Inanc, Mevlude) [5] ; Özçelik, M (Ozcelik, Melike) [6] ;
(provided by Clarivate)
Source
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume
14
Issue
2
Page
E145-E151
DOI
10.1111/ajco.12685
Published
APR 2018
Indexed
2018-04-02
Document Type
Article
Abstract
Translate AimThe goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues.
MethodsDemographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively.
ResultsThe median duration of GnRH analogues use was 2213.6 (range, 1-87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4-12 months (Group A), 13-24 months (Group B) and 25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 +/- 30.3 (range, 4-188) months. The OS in patients 35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000).
ConclusionThere is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use.
Keywords
Author Keywords
breast cancer medical oncology pharmacy
Clinical and Pathologic Features of Patients with Rare Ovarian Tumors: Multi-Center Review of 167 Patients by the Anatolian Society of Medical Oncology
By
Bilici, A (Bilici, Ahmet) [1] ; Inanc, M (Inanc, Mevlude) [2] ; Ulas, A (Ulas, Arife) [3] ; Akman, T (Akman, Tulay) ; Seker, M (Seker, Mesut) [4] ; Babacan, NA (Babacan, Nalan Akgul) [5] ; Inal, A (Inal, Ali) [6] ; Bal, O (Bal, Oznur) [3] ; Koral, L (Koral, Lokman) [7] ; Sevinc, A (Sevinc, Alper) [8] ;
(provided by Clarivate)
Source
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
Volume
14
Issue
11
Page
6493-6499
DOI
10.7314/APJCP.2013.14.11.6493
Published
2013
Indexed
2014-02-26
Document Type
Article
Abstract
Translate Background: Non-epithelial malignant ovarian tumors and clear cell carcinomas, Brenner tumors, transitional cell tumors, and carcinoid tumors of the ovary are rare ovarian tumors (ROTs). In this study, our aim was to determine the clinicopathological features of ROT patients and prognostic factors associated with survival. Materials and Methods: A total of 167 patients with ROT who underwent initial surgery were retrospectively analyzed. Prognostic factors that may influence the survival of patients were evaluated by univariate and multivariate analyses. Results: Of 167 patients, 75 (44.9%) were diagnosed with germ-cell tumors (GCT) and 68 (40.7%) with sex cord-stromal tumors (SCST); the remaining 24 had other rare ovarian histologies. Significant differences were found between ROT groups with respect to age at diagnosis, tumor localization, initial surgery type, tumor size, tumor grade, and FIGO stage. Three-year progression-free survival (PFS) rates and median PFS intervals for patients with other ROT were worse than those of patients with GCT and SCST (41.8% vs 79.6% vs 77.1% and 30.2 vs 72 vs 150 months, respectively; p=0.01). Moreover, the 3-year overall survival (OS) rates and median OS times for patients with both GCT and SCST were better as compared to patients with other ROT, but these differences were not statistically significant (87.7% vs 88.8% vs 73.9% and 170 vs 122 vs 91 months, respectively; p=0.20). In the univariate analysis, tumor localization (p<0.001), FIGO stage (p<0.001), and tumor grade (p=0.04) were significant prognostic factors for PFS. For OS, the univariate analysis indicated that tumor localization (p=0.01), FIGO stage (p=0.001), and recurrence (p<0.001) were important prognostic indicators. Multivariate analysis showed that FIGO stage for PFS (p=0.001, HR: 0.11) and the presence of recurrence (p=0.02, HR: 0.54) for OS were independent prognostic factors. Conclusions: ROTs should be evaluated separately from epithelial ovarian cancers because of their different biological features and natural history. Due to the rarity of these tumors, determination of relevant prognostic factors as a group may help as a guide for more appropriate adjuvant or recurrent therapies for ROTs.
Keywords
Author Keywords
Rare ovarian tumors overall survival progression-free survival prognostic factors
A View from Young Oncologists on Clinical Trials in Turkey: Obstacles and Solution Proposals
By
Akman, T (Akman, Tulay) [1] ; Tanriverdi, O (Tanriverdi, Ozgur) [2] ; Ozturk, MA (Ozturk, Mehmet A.) [3] ; Petekkaya, I (Petekkaya, Ibrahim) [4] ; Bakkal, H (Bakkal, Hakan) [5] ; Sonmez, OU (Sonmez, Ozlem U.) [6] ; Avci, N (Avci, Nilufer) [7] ; Zengin, S (Zengin, Seyda) [8] ; Aksu, G (Aksu, Gorkem) [9] ; Ozyigit, G (Ozyigit, Gokhan) [10] ;
(provided by Clarivate)
Source
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
Volume
24
Issue
3
Page
195-201
DOI
10.4999/uhod.14428
Published
2014
Indexed
2014-10-29
Document Type
Review
Abstract
Translate There is a new improvement in oncology nearly in every day as a result of preclinical or clinical. As the number of publication per capita, Turkey is far behind the other developed European countries. For example, the number of publications in oncology field is 2.134.964 in the world, it is 15.576 in our country. The most important obstacles for clinical trials in Turkey may be listed as financial problems, difficulties of working conditions, time limitation due to work intensity, inadequate experienced/trained man-power, absence of assistance team at all steps of a scientific trial, difficulties faced during project planning and ethics committee submissions, and lack of motivation. In this article, we, as young oncologists, aimed to discuss the place of Turkey in areas of scientific and clinical trials in the world; underlying causes for inadequate number, type and quality of national studies and possible solution proposals in our country.
Keywords
Author Keywords
Oncology Clinical trials Turkey
Salvage Treatment Experience in Advanced Synovial Sarcoma: a Multicenter Retrospective Analysis of the Anatolian Society of Medical Oncology
By
Yetisyigit, T (Yetisyigit, Tarkan) [1] ; Arpaci, E (Arpaci, Erkan) [2] ; Seber, ES (Seber, Erdogan Selcuk) [5] ; Kucukoner, M (Kucukoner, Mehmet) [8] ; Kos, FT (Kos, Fatma Tugba) [3] ; Sonmez, OU (Sonmez, Ozlem Uysal) [2] ; Alici, S (Alici, Suleyman) [6] ; Akman, T (Akman, Tulay) [9] ; Aktas, B (Aktas, Bilge) [5] ; Yildiz, R (Yildiz, Ramazan) [7] ;
(provided by Clarivate)
Source
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
Volume
14
Issue
9
Page
5185-5188
DOI
10.7314/APJCP.2013.14.9.5185
Published
2013
Indexed
2014-01-01
Document Type
Article
Abstract
Translate Background: We aimed to evaluate prognostic factors and response rates to various treatment approaches to patients with synovial sarcoma in an advanced setting. Materials and Methods: We retrospectively reviewed the medical records of 55 patients (18 pts; 32.7% women) diagnosed with synovial sarcomas. Twenty had metastatic disease at the time of diagnosis while the remainder of the study group consisted of patients who developed metastatic or inoperable locally advanced disease during follow up. Results: The median follow up time was 15 months (range: 1-53). Regarding outcomes for the 55 patients, 3 and 5 year overall survival rates were 26% and 14%, respectively. In univariate analyses among demographic factors female gender was associated with a better outcome (p=0.030). Patients with early progressing disease (<2 years) had a worse prognosis when compared to patient group with late relapse, but this difference did not reach statistical significance (p=0.056). According to multivariate Cox regression analysis patients who had undergone metastasectomy had a significant survival advantage (p=0.044). The overall response rate to different salvage chemotherapy regimens given as second line treatment was around 42.9-53.9% for all regimes. There were no statistically significant differences between chemotherapy regimens given in either second or third line settings in terms of overall survival. Conclusions: We observed no major differences in terms of response rate and survival between different salvage chemotherapy regimens. Although metastatic disease still carries a poor prognosis, metastasectomy was found to be associated with improved survival
Pathologic and Clinical Characteristics of Elderly Patients With Breast Cancer: A Retrospective Analysis of a Multicenter Study (Anatolian Society of Medical Oncology)
By
Inal, A (Inal, Ali) [1] ; Akman, T (Akman, Tulay) [2] ; Yaman, S (Yaman, Sebnem) [3] ; Ozturk, SC (Ozturk, Selcuk Cemil) [4] ; Geredeli, C (Geredeli, Caglayan) [5] ; Bilici, M (Bilici, Mehmet) [6] ; Inanc, M (Inanc, Mevlude) [7] ; Harputoglu, H (Harputoglu, Hakan) [8] ; Demirci, U (Demirci, Umut) [9] ; Balakan, O (Balakan, Ozan) [10] ;
(provided by Clarivate)
Source
Volume
99
Issue
1
Page
2-7
DOI
10.9738/INTSURG-D-13-00010
Published
JAN-FEB 2014
Indexed
2014-02-19
Document Type
Article
Abstract
Translate There is very little information about breast cancer characteristics, treatment choices, and survival among elderly patients. The purpose of this multicenter retrospective study was to examine the clinical, pathologic, and biologic characteristics of 620 breast cancer patients age 70 years or older. Between June 1991 and May 2012, 620 patients with breast cancer, recruited from 16 institutions, were enrolled in the retrospective study. Patients had smaller tumors at diagnosis; only 15% of patients had tumors larger than 5 cm. The number of patients who had no axillary lymph node involvement was 203 (32.7%). Ninety-three patients (15.0%) had metastatic disease at diagnosis. Patients were characterized by a higher fraction of pure lobular carcinomas (75.3%). The tumors of the elderly patients were also more frequently estrogen receptor (ER) positive (75.2%) and progesterone receptor (PR) positive (67.3%). The local and systemic therapies for breast cancer differed according to age. An association between age and overall survival has not been demonstrated in elderly patients with breast cancer. In conclusion, the biologic behavior of older patients with breast cancer differs from younger patients, and older patients receive different treatments.
Keywords
Author Keywords
Breast cancer Elderly patients Clinical characteristics Pathologic characteristics
Clinicopathological Features in Bilateral Breast Cancer
By
Baykara, M (Baykara, Meltem) [1] , [2] ; Ozturk, SC (Ozturk, Selcuk Cemil) [1] , [2] ; Buyukberber, S (Buyukberber, Suleyman) [1] , [2] ; Helvaci, K (Helvaci, Kaan) [1] , [3] ; Ozdemir, N (Ozdemir, Nuriye) [1] , [5] ; Alkis, N (Alkis, Necati) [1] , [3] ; Berk, V (Berk, Veli) [1] , [6] ; Koca, D (Koca, Dogan) [1] , [7] ; Coskun, U (Coskun, Ugur) [1] , [2] ; Oksuzoglu, B (Oksuzoglu, Berna) [1] , [3] ;
(provided by Clarivate)
Source
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
Volume
13
Issue
9
Page
4571-4575
DOI
10.7314/APJCP.2012.13.9.4571
Published
2012
Indexed
2013-01-02
Document Type
Article
Abstract
Translate Introduction and Purpose: The frequency of bilateral breast cancer is 1.4-11.0% among all breast cancers. It can present as synchronous (SC) or metachronous (MC). Data regarding clinical course of bilateral breast cancer are scarce. In this study, we therefore evaluated demographic, pathological and clinical characteristics, treatments and responses in bilateral breast cancer cases; making distinctions between metachronous-synchronous and comparing with historic one-sided data for the same parameters. Materials and Methods: One hundred fifty bilateral breast cancer cases from ten different centers between 2000 and 2011 were retrospectively scanned. Age of the cases, family history, menopausal status, pathological features, pathological stages, neoadjuvant, surgery, adjuvant and palliative chemotherapy/radiotherapy were examined in the context of the first and second occurrence and discussed with reference to the literature. Results: Metachronous and synchronous groups showed similar age, menopausal status, tumor type, HER2/neu expression; the family history tumor grade, tumor stage, ER-negativity rate, local and distant metastases rates, surgery, adjuvant chemotherapy application rates were identified as significantly different. Palliative chemotherapy response rate was greater in the metachronous group but median PFS rates did not differ between the groups. Conclusion: Although bilateral breast cancer is not frequent, MC breast cancer is different from SC breast cancer by having more advanced grade, stage, less ER expression, more frequent rates of local relapse and distant metastasis and better response to chemotherapy in case of relapse/metastasis.
Keywords
Author Keywords
Bilateral breast cancer synchronous metachronous clinicopathological characteristics Turkey
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer
By
Tonyali, O (Tonyali, Onder) [1] ; Coskun, U (Coskun, Ugur) [1] ; Sener, N (Sener, Nur) [2] ; Inanc, M (Inanc, Mevlude) [3] ; Akman, T (Akman, Tulay) [4] ; Oksuzoglu, B (Oksuzoglu, Berna) [5] ; Ozdemir, NY (Ozdemir, Nuriye Yildirim) [6] ; Yazilitas, D (Yazilitas, Dogan) [7] ; Benekli, M (Benekli, Mustafa) [1] ; Uner, A (Uner, Aytug) [1] ;
Group Author
ASMO (ASMO)
(provided by Clarivate)
Source
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume
138
Issue
12
Page
2145-2151
DOI
10.1007/s00432-012-1296-x
Published
DEC 2012
Indexed
2012-12-05
Document Type
Article
Abstract
Translate Purposes Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.
Methods In this multicenter study, the medical records of all patients with EBC were analyzed in 8 centers retrospectively. Totally consecutive, 479 female patients who received trastuzumab in the adjuvant treatment were evaluated for disease-free survival (DFS), overall survival (OS), efficacy, and toxicity.
Results There were 181 (37.8 %) and 298 (62.2 %) patients in the 9- and 52-week trastuzumab groups, respectively. Median follow-up was 30.6 months (5.7-68.9) in the 9-week trastuzumab group and 29.3 months (5.9-59.6) in the 52-week trastuzumab group. Thirty-six month DFS was 90 and 85 % (P = 0.132) in the 9- and 52-week trastuzumab treatment groups, respectively, and 36-month OS was 96 and 97 % in the 9- and 52-week trastuzumab groups, respectively (P = 0.779). Symptomatic cardiotoxicity was observed in 1 (0.6 %) patient in the 9-week trastuzumab group and in 4 (1.3 %) patients in the 52-week trastuzumab group.
Conclusions In this study, similar outcomes were found in the 9- and 52-week trastuzumab treatment groups.
Keywords
Author Keywords
Trastuzumab Adjuvant therapy Breast cancer HER2
Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology
By
Uyeturk, U (Uyeturk, Ummugul) [1] ; Oksuzoglu, B (Oksuzoglu, Berna) [2] ; Akman, T (Akman, Tulay) [3] ; Turker, I (Turker, Ibrahim) [4] ; Sener, N (Sener, Nur) [5] ; Tastekin, D (Tastekin, Didem) [6] ; Bal, O (Bal, Oznur) [2] ; Berk, V (Berk, Veli) [7] ; Arslan, UY (Arslan, Ulku Yalcintas) [2] ; Urakci, Z (Urakci, Zuhat) [8] ;
(provided by Clarivate)
Source
Volume
31
Issue
4
DOI
10.1007/s12032-014-0929-0
Article Number
929
Published
APR 2014
Indexed
2014-05-15
Document Type
Article
Abstract
Translate Primary metastatic breast cancer (PMBC) comprises 3-10 % of all BCs. PMBC is a heterogeneous disease. To date, little is known about the tumor characteristics, treatment results, and overall survival ( OS) of patients with PMBC. Patients were considered to have PMBC if distant metastasis was evident within 3 months of the initial diagnosis of BC. Between September 2007 and April 2013, 466 PMBC patients were included in this study and analyzed retrospectively. The median age of the patients was 50 (18- 90) years. Bone/ soft tissue metastases were more frequent in the hormone receptor (HR)(+) human epidermal growth factor receptor ( HER) 2(-) group compared with the HR(-) HER2(-) and HR(-) HER2(-) groups ( p < 0.001), whereas visceral organ metastasis was more frequent in the HR(-) HER2(-) and HR(-) HER2(-) groups ( p < 0.001). The OS was affected by Eastern Cooperative Oncology Group performance status, tumor histology, receptor status, and the site of metastasis ( p < 0.001, p < 0.001, p < 0.001, and p = 0.011, respectively). According to the first-line systemic treatment choices of the patients, the longest median OS was observed in the HR(?) HER2(-) group who received hormonotherapy combined with trastuzumab after chemotherapy ( 86 months, 95 % CI 23.8-148.1) and the shortest median OS was observed in the HR(-) HER2(-) group who received chemotherapy only ( 24 months, 95 % CI 17.9-30.0) ( p < 0.001). Bisphosphonate therapy or radiotherapy had no significant effect on OS ( p = 0.733, 0.603). In multivariate analysis, hormonotherapy, chemotherapy + trastuzumab, trastuzumab + hormonotherapy following chemotherapy, and surgery were the most important prognostic factors for OS, respectively ( p < 0.001, p = 0.025, p = 0.027, p = 0.029). The general characteristics of the primary tumor are important for the prognosis and survival of patients with PMBC. Interestingly, patients who underwent primary breast tumor surgery, even those at the metastatic stage upon admission, had the longest survival.
Keywords
Author Keywords
Primary metastatic breast carcinoma Treatment Operation Survival
The factors that have an impact on the development of brain metastasis in the patients with breast cancer
By
Dayan, A (Dayan, Adem) [1] ; Koca, D (Koca, Dogan) [1] ; Akman, T (Akman, Tulay) [1] ; Oztop, I (Oztop, Ilhan) [1] ; Ellidokuz, H (Ellidokuz, Hulya) [2] ; Yilmaz, U (Yilmaz, Ugur) [1]
(provided by Clarivate)
Source
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Volume
8
Issue
4
Page
542-548
DOI
10.4103/0973-1482.106531
Published
OCT-DEC 2012
Indexed
2013-04-03
Document Type
Article
Abstract
Translate Background: To evaluate the factors that have an impact on the development of brain metastasis in patients with breast cancer.
Materials and Methods: Among the patients who were followed-up and treated for breast cancer between January 2000 and January 2010, the ones with brain metastasis were included to the analysis. Metastatic breast cancer patients without brain metastasis, which had similar duration of follow-up and median age were included as the control group. Both group were compared for prognostic and predictive factors in terms of relationship between with or without brain metastasis and survival.
Results: There were a total of 63 female patients with metastatic breast cancer who had brain metastasis and the researchers enrolled the same number of female patients as the control group. In the univariate analysis, as a significant finding, it was found that, the patients with breast cancer who had brain metastasis had vascular invasion positivity, human epidermal growth factor receptor-2 (HER-2) positivity, a rare detection of invasive lobular carcinoma component in the tumor, estrogen receptor negativity, and no bone and liver metastasis and they did not receive chemotherapy due to several reasons after the detection of metastasis in any organ. In the multivariate analysis, HER-2 positivity, no bone and liver metastasis and not receiving chemotherapy due to several reasons after the detection of metastasis in any organ were detected as significant findings.
Conclusions: As the prognostic and predictive factors showing the development of brain metastasis in breast cancer patients may be identified, follow-up also including the brain is important in order to take preventive measures.
Keywords
Author Keywords
Breast cancer brain metastasis prognostic and predictive factors survival
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma
By
Unek, IT (Unek, Ilkay Tugba) [1] , [2] ; Akman, T (Akman, Tulay) [1] ; Oztop, I (Oztop, Ilhan) [1] ; Unal, OU (Unal, Olcun Umit) [1] ; Salman, T (Salman, Tarik) [1] ; Yilmaz, U (Yilmaz, Ugur) [1]
(provided by Clarivate)
Source
Volume
16
Issue
3
Page
428-434
DOI
10.1007/s10120-012-0206-x
Published
JUL 2013
Indexed
2013-08-14
Document Type
Article
Abstract
Translate The combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) is an effective but highly toxic regimen for the treatment of advanced gastric cancer. To improve tolerability while maintaining the efficacy of the DCF regimen, we developed a modified DCF regimen including an infusional 5-fluorouracil administration according to the de Gramont regimen.
In this study, 70 patients with advanced gastric cancer were treated. Each 2-week cycle consisted of docetaxel (60 mg/m(2)), cisplatin (50 mg/m(2)), a 5-fluorouracil (400 mg/m(2)) IV bolus, and 5-fluorouracil (2,400 mg/m(2)) IV over 46 h plus leucovorin (400 mg/m(2)) IV over 2 h.
The median progression-free survival and overall survival were 9.0 months (95 % CI, 7.1-10.9) and 10.8 months (95 % CI, 7.4-14.2), respectively; the 1-year and 2-year overall survival rates were 46.3 and 18.4 %, respectively. Twenty-nine (41.4 %) partial responses, 19 (27.1 %) stable disease, and 22 (31.4 %) progression of disease were observed. Grade 3-4 toxicities included neutropenia (37.1 %), febrile neutropenia (15.7 %), thrombocytopenia (10.0 %), anemia (8.6 %), nausea and vomiting (10.0 %), stomatitis (5.7 %), infection (8.6 %), and diarrhea (2.9 %).
Our results show that a de Gramont-based DCF regimen may have tolerable toxicities and be an effective and convenient palliative treatment for advanced gastric cancer.
Keywords
Author Keywords
Advanced gastric cancer Docetaxel CisplatinLeucovorin5-Fluorouracil
Is lymph node ratio prognostic factor for survival in elderly patients with node positive breast cancer? The Anatolian Society of Medical Oncology
By
Inal, A (Inal, Ali) [1] ; Akman, T (Akman, Tulay) [2] ; Yaman, S (Yaman, Sebnem) [3] ; Ozturk, SC (Ozturk, Selcuk Cemil) [4] ; Geredeli, C (Geredeli, Caglayan) [5] ; Bilici, M (Bilici, Mehmet) [6] ; Inanc, M (Inanc, Mevlude) [7] ; Harputoglu, H (Harputoglu, Hakan) [8] ; Demirci, U (Demirci, Umut) [9] ; Suner, A (Suner, Ali) [10] ;
(provided by Clarivate)
Source
Volume
84
Issue
2
Page
143-148
Published
MAR-APR 2013
Indexed
2013-07-17
Document Type
Article
Abstract
Translate Several studies have now demonstrated that the lymph node ratio (LNR), as a superior indicator of axillary tumor burden to the number of excised nodes. While, about the prognostic value of LNR on the the survival of elderly patients is limited. The aim of this retrospective multicenter study is to evaluate the prognostic value of lymph node ratio in elderly patients with node positive breast cancer.
METHODS: Onehundredeightyfour patient with operable breast cancer, recruited from 17 institutions, were enrolled into the retrospectively study. Eleven potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival.
RESULT: Among the eleven variables of univariate analysis, four variables were identified to have prognostic significance for Overall survival (OS): pathologic tumor size (T), No. of positive nodes (N), LNR and estrogen receptor-positive (ER). Among the eleven variables of univariate analysis, two variables were identified to have prognostic significance for Disease-free survival (DFS): N and LNR. Multivariate analysis by Cox proportional hazard model showed that 7; LNR and ER were considered independent prognostic factors for OS. Furthermore, LNR was considered independent prognostic factors for DFS.
CONCLUSION: In conclusion, the LNR was associated with the prognostic importance for DFS and OS in elderly patients who were administered adjuvant treatments.
Keywords
Author Keywords
Breast cancer Elderly patients Lymph Node Ratio
Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study
By
Unal, OU (Unal, Olcun Umit) [1] ; Yilmaz, AU (Yilmaz, Ahmet Ugur) [2] ; Yavuzsen, T (Yavuzsen, Tugba) [3] ; Akman, T (Akman, Tulay) [3] ; Ellidokuz, H (Ellidokuz, Hulya) [4]
(provided by Clarivate)
Source
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
Volume
15
Issue
15
Page
6165-6169
DOI
10.7314/APJCP.2014.15.15.6165
Published
2014
Indexed
2014-11-28
Document Type
Article
Abstract
Translate Background: The advantage of intra-peritoneal (IP) chemotherapy (CT) in the initial management of ovarian cancer after cytoreductive surgery is well known. The feasibility and toxicity of a treatment regimen with an IP + intravenous CT (IPIVCT) for optimally debulked stage III ovarian cancer were here evaluated retrospectively. Materials and Methods: A total of 30 patients were treated in our institution between October 2006 and February 2011. Patients received IV paclitaxel 175 mg/m(2) over 3 hours followed by IP cisplatin 75 mg/m(2) on day 1; they also received IP paclitaxel 60 mg/m(2) on day 8. They were also scheduled to receive 6 courses of CT every 21 days. Results: The median age of the patients was 55 years (35-77), and the majority had papillary serous ovarian cancer (63.3%). The patients completed a total of 146 cycles of IPIVCT. Twenty-eight were able to receive at least three cycles of IPIVCT and 18 (60%) completed the scheduled 6 cycles. Two patients discontinued the IPIVCT because of toxicity of chemotherapy agents and 6 had to stop treatment due to intolerable abdominal pain during IP drug administration, obstruction and impaired access. Grade 3/4 toxicities included neutropenia (6 patients; 20%), anemia (2 patients; 6.7%) and nausea-vomiting (2 patients; 6.7%). Doses were delayed in 12 cycles (8%) for neutropenia (n=6), thrombocytopenia (n=3) and elevated creatinine (n=3). Drug doses were not reduced. The median duration of progression-free survival (PFS) was 47.7 months (95% CI, 38.98-56.44) and overall survival (OS) was 51.7 months (95% CI, 44.13-59.29). Two and five-year overall survival rates were 75.6 % and 64.8%, respectively. Conclusions: IPIVCT is feasible and well-tolerated in this setting. Its clinically proven advantages should be taken into consideration and more efforts should be made to administer IPIVCT to suitable patients.
Keywords
Author Keywords
Ovarian cancer intra-peritoneal chemotherapyintra-venous chemotherapy
Impact of Accompanying Comorbidities on Survival in Patients with Stage IIIB- IV Non-Small-Cell Lung Cancer
By
Demirpence, M (Demirpence, Mustafa) [1] ; Akman, T (Akman, Tulay) [2] ; Oztop, I (Oztop, Ilhan) [3] ; Unek, IT (Unek, Ilkay T.) [2] ; Yavuzsen, T (Yavuzsen, Tugba) [3] ; Yilmaz, AU (Yilmaz, Ahmet U.) [4]
(provided by Clarivate)
Source
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
Volume
24
Issue
4
Page
223-232
DOI
10.4999/uhod.14471
Published
2014
Indexed
2015-02-17
Document Type
Article
Abstract
Translate The aim of the study was to investigate the impact of accompanying comorbidities on survival in non-small-cell lung carcinoma (NSCLC) patients. A total of 221 patients with stage IIIB- IV NSLC between May 1998 and April 2009 were included. Survival data was analyzed according to age (those younger than 65 and those 65 and older) and Charlson Comorbidity Index (CCI) scores. Eighty-six (39%) patients were aged 65 and older, and the remaining 135 (61%) were younger than 65. In the 65 and over group the median survival of patients was 44 months for CCI Group 0, 16 months for CCI Group 1, 10 months for CCI Group 2, and 10 months for CCI Group 3. For the younger group, the median survival time was 19 months for CCI Group 0, 18 months for CCI Group 1, 11 months for CCI Group 2, and 11 months for CCI Group 3. There were no statistically significant differences in the comorbidity factors regarding survival in the two groups of patients. In conclusion, the frequency of comorbidity factors increased in stage IIIB and IV NSCLC patients as age increased. Although survival in patients with higher CCI scores was shorter, the CCI was not associated with survival for patients having local advanced and metastatic disease; no significant difference was found statistically for these patients. Therefore, these patients need to be managed more thoroughly.
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)
By
Demirci, U (Demirci, Umut) [1] ; Tufan, G (Tufan, Gulnihal) [2] ; Aktas, B (Aktas, Bilge) [3] ; Balakan, O (Balakan, Ozan) [4] ; Alacacioglu, A (Alacacioglu, Ahmet) [5] ; Dane, F (Dane, Faysal) [3] ; Engin, H (Engin, Huseyin) [6] ; Kaplan, MA (Kaplan, M. Ali) [7] ; Gunaydin, Y (Gunaydin, Yusuf) [2] ; Ozdemir, NY (Ozdemir, Nuriye Y.) [8] ;
(provided by Clarivate)
Source
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume
139
Issue
5
Page
829-835
DOI
10.1007/s00432-013-1390-8
Published
MAY 2013
Indexed
2013-05-15
Document Type
Article
Abstract
Translate The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.
A total of 115 patients with grade IV glial tumor (n = 93) and grade III glial tumor (n = 22) were retrospectively evaluated at 14 centers in Turkey. Primary objectives of the study were to evaluate the efficacy and toxicity of the bevacizumab and irinotecan as salvage treatment based on response to therapy, progression-free survival (PFS), 6 months of PFS, overall survival (OS), and 6 months of OS (OS6).
Bevacizumab and irinotecan were performed as second line (79.1 %) and third line treatment (20.9 %). Median chemotherapy cycle was 6 (range 1-37), and median follow-up was 6 months (range 1-36 months). Objective response rate was 39.1 %. Six-month PFS and OS6 were 46.3 % and 67.5 %, respectively. Median PFS was 6 months (95 % CI 2.5-9.5) and 6 months (95 % CI 4.9-7.1) in the grade III and IV groups, respectively (p = 0.773). Median OS was 9 months (95 % CI 7.1-10.9) and 8 months (95 % CI 6.6-9.4) in the grade III and IV groups, respectively (p = 0.450). Serious toxicities were observed in 7.8 % of patients. Treatment-related toxic death was observed in 3 patients. There was no treatment related to central nervous system hemorrhage or other serious hemorrhages.
Present study results were consistent with previous studies. In addition, we detected similar outcomes in grade III and IV glial tumors.
Keywords
Author Keywords
Bevacizumab Irinotecan Recurrent disease Malignant glioma
Is there any effect of lower extremity deep vein thrombosis which proven by Doppler ultrasonography on cancer recurrence in patients with stage III colon cancer? A study of the Turkish Descriptive Oncological Researches Group
By
Tanriverdi, O (Tanriverdi, Ozgur) [1] ; Yildirim, B (Yildirim, Birdal) [2] ; Gul, S (Gul, Suha) [3] ; Cevik, E (Cevik, Esin) [4] ; Akman, T (Akman, Tulay) [5] ; Cokmert, S (Cokmert, Suna) [6] ; Pilanci, KN (Pilanci, Kezban Nur) [7] ; Avci, N (Avci, Nilufer) [8] ; Ordu, C (Ordu, Cetin) [7] ; Barutca, S (Barutca, Sabri) [4]
(provided by Clarivate)
Source
Volume
31
Issue
10
DOI
10.1007/s12032-014-0215-1
Article Number
215
Published
OCT 2014
Indexed
2014-10-15
Document Type
Article
Abstract
Translate This study aimed to determine the predictive value of lower extremity deep vein thrombosis (LE-DVT) on first cancer recurrence in patients with stage III colon cancer. A total of 113 eligible patients with stage III colon cancer were divided into two groups according to whether they had LE-DVT. LE-DVT was detected in 29 (26 %) patients. Presence of recurrence with distant metastasis had a significant positive correlation with baseline platelet count, baseline mean platelet volume, and the presence of lower extremity deep vein thrombosis. It was concluded that the relation between disease progression and the presence of LE-DVT in stage III colon cancer is independent of other study variables (P = 0.031; OR = 4.27; 95 % CI 1.89-6.71). We hypothesized that the presence of LE-DVT in patients with stage III colon cancer may predict to early cancer recurrence with distant metastasis.
Keywords
Author Keywords
Deep vein thrombosis Colon cancer Disease progression
Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab
By
Tonyali, O (Tonyali, Onder) [1] ; Coskun, U (Coskun, Ugur) [1] ; Sener, N (Sener, Nur) [2] ; Inanc, M (Inanc, Mevlude) [3] ; Akman, T (Akman, Tulay) [4] ; Ulas, A (Ulas, Arife) [5] ; Yazilitas, D (Yazilitas, Dogan) [6] ; Bal, O (Bal, Oznur) [7] ; Kucukoner, M (Kucukoner, Mehmet) [8] ; Ozdemir, NY (Ozdemir, Nuriye Yildirim) [9] ;
Group Author
ASMO (ASMO)
(provided by Clarivate)
Source
Volume
36
Issue
10
Page
554-558
DOI
10.1159/000355156
Published
OCT 2013
Indexed
2013-11-08
Document Type
Article
Abstract
Translate Background: The objective of this study was to identify prognostic factors affecting the recurrence-free survival (RFS) in patients who received a 52-week trastuzumab therapy for HER2-positive early stage breast cancer (EBC). Patients and Methods: The medical records of all patients with EBC from 10 centers were analyzed. Pathologic and clinical tumor characteristics were evaluated in 424 female patients who received 52 weeks of adjuvant trastuzumab for HER2-positive EBC. Survival was estimated using the Kaplan-Meier method. Univariate analyses of RFS were performed with the log-rank test. Independent prognostic and predictive factors affecting RFS were assessed by Cox regression analysis. Results: Median follow-up time was 33.1 months (range 9.2-75.9 months). 3-year RFS and overall survival were 87 and 97%, respectively. In multivariate analysis, patients aged 70 years or over (p = 0.017, relative risk (RR) 2.7, 95% confidence interval (CI) 1.19-6.13), patients with > 9 positive lymph nodes (p = 0.001, RR 2.52, 95% CI 1.42-4.46), and those with progesterone receptor-negative tumors (p = 0.006, RR 2.33, 95% CI 1.27-4.27) had worse RFS. Conclusion: In spite of a 52-week adjuvant trastuzumab treatment, classic poor prognostic factors for invasive EBC remained as such in patients with HER2-positive EBC.
Keywords
Author Keywords
Breast cancer Early disease Trastuzumab Adjuvant treatmentHER2Prognosis
Bimonthly Regimen of High-Dose Leucovorin, Infusional 5-Fluorouracil, Epirubicin and Cisplatin (Modified ECF) as Adjuvant Chemotherapy in Resected Gastric Adenocarcinoma
By
Unek, IT (Unek, Ilkay Tugba) [1] ; Unek, T (Unek, Tarkan) [2] ; Oztop, I (Oztop, Ilhan) [1] ; Akman, T (Akman, Tulay) [1] ; Atilla, K (Atilla, Koray) [2] ; Ellidokuz, H (Ellidokuz, Hulya) [4] ; Bora, S (Bora, Seymen) [2] ; Sarioglu, S (Sarioglu, Sulen) [3] ; Yilmaz, U (Yilmaz, Ugur) [1]
(provided by Clarivate)
Source
Volume
58
Issue
3
Page
233-240
DOI
10.1159/000339493
Published
2012
Indexed
2012-09-19
Document Type
Article
Abstract
Translate Background: The administration of the de Gramont regimen in combination with cisplatin and epirubicin (modified ECF) has previously been reported as a treatment for advanced gastric cancer, but here we report this regimen combination in an adjuvant setting for the first time. Methods: Forty-eight patients with curatively resected gastric cancer were treated. Each 2-week cycle consisted of epirubicin (50 mg/m(2)), cisplatin (50 mg/m(2)), 5-fluorouracil (5-FU) IV bolus (400 mg/m(2)) and 5-FU IV (2,400 mg/m(2)) over 46 h plus leucovorin IV (400 mg/m(2)) over 2 h. Postoperative chemoradiotherapy was also administered to the patients when indicated. We retrospectively reviewed the patients who were treated with modified ECF. Results: The median disease-free survival (DFS) was 40.7 months and the 1-, 3- and 5-year DFS rates were 78.5, 55.7 and 44.6%, respectively. The most common grade 3-4 toxicities were hematological and gastrointestinal. Conclusion: A modified ECF regimen may be an effective and convenient treatment with tolerable toxicities for the adjuvant treatment of gastric cancer. It may provide an alternative regimen to the standard ECF when a continuous ambulatory infusion pump is not feasible or not preferred by the patient. Copyright (C) 2012 S. Karger AG, Basel
Keywords
Author Keywords
Gastric cancer Epirubicin Cisplatin Leucovorin5-Fluorouracil Adjuvant chemotherapy
Attitudes of cancer patients after diagnosis: How cancer affects social life? A Turkish Oncology Group study
By
Nayir, E (Nayir, Erdinc) [1] ; Koyuncu, MB (Koyuncu, Mahmut Bakir) [2] ; Esin, E (Esin, Ece) [3] ; Turker, I (Turker, Ibrahim) [4] ; Tanriverdi, O (Tanriverdi, Ozgur) [5] ; Uysal, M (Uysal, Mukremin) [6] ; Er, O (Er, Ozlem) [7] ; Demir, A (Demir, Atakan) [8] ; Akman, TT (Akman, Tulay Tuzel) [9] ; Pilanci, KN (Pilanci, Kezban Nur) [10] ;
(provided by Clarivate)
Source
Volume
22
Issue
1
Page
208-213
Published
JAN-FEB 2017
Indexed
2017-03-31
Document Type
Article
Abstract
Translate Purpose: Each year, 12.7 million people learn that they have cancer and 8.2 million people die of= cancer worldwide. Cancer is a major public health issue which causes fundamental changes in the lives of patients and their families. The purpose of this study was to evaluate the lives of patients after diagnosis and determine the changes in their lifestyles.
Methods: Between September 2013 to December 2013, a questionnaire consisting of 22 questions was administered during a face to face interview to patients at 13 different Oncology Units in Turkey. Each patient was queried during the administration of his/her chemotherapy. Eight of the questions featured independent choices, and 14 had dependent (multiple) choices.
Results: A total of 1300 patients were included in the study. Of patients 9.5% were 71 years of age and older which was the oldest age group. The mean patient age was 54.6 +/- 13.8 years. Of the whole group of patients 58.5% were female and 41.5% male. After diagnosis, 64% of the patients reported that they were complying with guidelines for a healthy lifestyle and 80% said that they were eating healthier food. At the time they filled in the questionnaire, more than half of the patients (57.3%) felt optimistic about their disease.
Conclusions: Diagnosis of cancer may change the patients' dietary and reading habits, social relationships, activities and more importantly, their point of life view.
Keywords
Author Keywords
Türk Tabipler Birliği
Türk Kanser Araştırma ve Savaş Derneği
Anadolu Tıbbi Onkoloji Derneği
Türk Tıbbi Onkoloji Derneği
Geriatrik Onkoloji Derneği
MASCC ( Multinational Association of Supportive Care in Cancer) Derneği
ESMO (European Society of Medical Oncology) Avrupa Medikal Onkoloji Derneği
ASCO (American Society of Medical Oncology) Amerikan Medikal Onkoloji Derneği